Dossier;Guideline;PDF link;;Report: Toxicokinetics;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;OECD;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;Team comments;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;observations;tissue distribution;% of dose systemically avaliable (bioavaliability);% of adminsitred dose in excreta;conclusion;;homogeneity;pH;concentration (%);composition;purity (%);solubility in vehicle;chemical batch nr;additional info;radiolabeling;;species/strain;source;age at start of experiment;sex;feed;n animals / group;;dose levels;administration scheme;IV;oral;dermal;inhalation;i.v.g;samples;sampling time;vehicle;SCCS comment to test;year;GLP;Ref. in dossier;additional info;own comment;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;in vivo-toxicokinetics, human: in a human metabolism study, one subject received 200 mg and two others received 500 mg p-aminophenol hydrochloride. route of administration was not indicated. ref: a2. SCCS comment: topically applied p-aminophenol results in systemic exposure only to APAP and/or its metabolites in both humans and animals. consequently, the systemic toxicity of p-aminophenol is mainly related to the toxicity of APAP. ;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
1,2,4-trihydroxybenzene ;;https://ec.europa.eu/health/sites/health/files/scientific_committees/consumer_safety/docs/sccs_o_222.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"the relative embryotoxicity of the NMP and its metabolites was evaluated using rat whole embryo culture (WEC) and the BALB/c 3T3 cytotoxicity test. the resulting data were evaluated using two strategies; namely, one based on using all endpoints determined in the WEC and the other including endpoints from both the WEC and the cytotoxicity test. on basis of the first analysis, the substance with the highest embryotoxic potential is NMP, followed by 5-HNMP, 2-HMSI and MSI. specific dysmorphogeneses induced by NMP and 5- HNMP were aberrations in the head region of the embryos, abnormal development of the second visceral arches and open neural pores. the second evaluation strategy used only two endpoints of the WEC, i.e. the no observed adverse effect concentration (NOAECWEC) and the lowest concentration leading to dysmorphogenesis in 100% of the cultured embryos (ICMax WEC). in addition to these WEC endpoints the IC50 3T3 from the cytotoxicity test (BALB/c 3T3 fibroblasts) was included in the evaluation scheme. these three endpoints were applied to a prediction model developed during a validation study of the ECVAM allowing the classification of the embryotoxic potential of each compound into three classes (non-, weakly- and strongly embryotoxic). consistent results from both evaluation strategies were observed, whereby NMP and its metabolites revealed a direct embryotoxic potential. hereby, only NMP and 5-HNMP induced specific embryotoxic effects and were classified as weakly embryotoxic, whereas the other two metabolites, 2-HMSI and MSI, were determined to be non-embryotoxic. the authors concluded that the results of this in vitro study support the hypothesis that NMP, the parent substance, is responsible for the embryotoxic effects observed in vivo whereby its main metabolite, 5-HNMP, may be involved to some extent. the latter metabolites (MSI, 2-HMSI) may be considered as detoxification steps. the authors pointed out that according to the general principles of allometry this would mean that in case of a non-inhalation route of exposure, e.g., after dermal exposure, humans should be about four times more sensitive than rats, unless comparative metabolism studies in rats and humans suggest something different. ref.: 60";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
1,2,4-trihydroxybenzene ;428;https://ec.europa.eu/health/sites/health/files/scientific_committees/consumer_safety/docs/sccs_o_222.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"the involvement of cytochrome P450 2E1 (CYP2E1) in the metabolism of NMP was studied with three experimental approaches: in the rat, in vitro in human microsomes, and in human volunteers. NMP was administered dermally (40 mg/kg bw) to OFA rats to examine the influence of CYP2E1 inhibition. CYP2E1 inhibition led to a statistically significant retardation of 5-HNMP excretion in urinary fractions collected during the first 12 h. in the group of fasted rats, a two-fold increase of CYP2E1activity was observed in comparison with the control group. during the first 6 h after dermal administration of NMP to fasted rats, about 33% of the dose was excreted in urine versus 22% in controls. in vitro, NMP (15 mM) was incubated (up to 120 min) with human liver microsomes and the formation of 5-HNMP followed michaelis-menten kinetics with Vmax of 1.1 nmol/min per mg protein and Km of 2.4 mM. the formation of 5-HNMP was inhibited by 35% in the presence of a monoclonal antibody against CYP2E1, but not by CYP1A2 antibody. in a dermal application experiment, 12 human volunteers were exposed by means of a dermal patch to 300 mg NMP; five urine fractions were collected during the 48 h following the onset of application in order to measure the major metabolites 5-HNMP and 2-HMSI. before NMP application, a blood sample was collected for the quantification of CYP2E1 mRNA in peripheral blood lymphocytes (PBLs). the mean dermal absorption of NMP was 67.9%. the highest amount of 5-HNMP was excreted in urine in the fraction collected between 6–12 h (12.6% of dose), while 2-HMSI peaked in fractions 12–24 h and 36–48 h (3.3 and 3.2% of dose, respectively). a significant relationship was found between CYP2E1 mRNA content in PBLs and the amount of both the metabolites excreted in urine within 24 h (r2=0.54, P<0.01). it is concluded that CYP2E1 is involved in the first steps of NMP metabolism in the rat and, to a lesser extent, in humans. ref.: 61";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
vitamin a;;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_199.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"cells: tc-7 (human intestinal epithelial);test substance: hydroxyethyl-2-nitro-p-toluidine; batch: 6718 Fass 10/20; purity: not specified in study but given as 99.8%, hplc 254 nm, submission iii; test concentration: 50 µM; vehicle: hbss buffer with 1% dmso; incubation: 60 min; glp: /; study period: 25 march – 5 april 2004. there is no official guideline for this in vitro method but it was performed according to ECVAM recommendations. two independent experiments were done.  the bioavailability of Hydroxyethyl-2-nitro-p-toluidine across the intestinal barrier was investigated at 370C in shaken 96-well plates for 60 min. the permeability from the apical (pH 6.5) to basolateral (pH 7.4) side of the epithelium was measured by HLPC-MS/MS and the apparent permeability coefficient (Papp) was calculated for the two experiments. 14Cmannitol (~4µM) was used to show the integrity of the cell monolayers; only monolayers with a permeability of <2x 10-6 cm/sec were used. propranolol, vincristine and ranitidine were used as concurrent reference material to show validity of the test system. ranitidine that has 50% absorption in humans is used as the low permeability reference (FDA). recovery for both the reference substances and Hydroxyethyl-2-nitro-p-toluidine was from 83 –100%. The reference substances propranolol (Papp 29.6 x 10-6 cm/sec) and ranitidine (Papp 0.4 x 10-6 cm/sec) respectively with 90% and ~50% absorption in humans indicate the validity of the assay. hydroxyethyl-2-nitro-p-toluidine was rated as having a high permeability with Papp 93.6 x 10-6 cm/sec, which would indicate very good intestinal absorption.  ";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
phenoxyethanol;;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_195.pdf;the mean cumulative recovery in the urine after 96 h was 62.2 (low dose) and 72.9% (high dose) while the figures for the faeces were 31.4% and 22.0%, respectively. The mean mass balance (oral) was ca. 98%.. after oral dosing three metabolites were observed in the urine, the largest peak was identified as N,N-diacetyl-toluene-2,5-diamine. following oral dosing of 2.5 and 25 mg/kg toluene-2,5-diamine the AUC values were 17.59 and 174 mgeq x h/l, respectively.;;>90;;;;;7;;;99.3 (radiochemical purity) 98.3 (non-labelled);;3362-259 [ring-U-14C]-toluene-2,5-diamine sulfate CFQ13783, batch 1 [ring-U-14C]- toluene-2,5-diamine sulfate and 2346 (non-labelled);toluene-2,5-diamine sulfate;[ring-U-14C]- toluene-2,5-diamine sulfate;;rat/wistar kyoto, WKY/NR Crl BR (inbred);;;f;;4 in the mass balance groups, 6  in the toxicokinetics groups;;2.5 or 25 mg/kg bw;;;yes;;;;urine and faeces;0-8, 8-24, 24-48, 48-72, 72-96 h intervals;water;the Kyoto strain was used because it is a slow acetylator phenotype.;;yes;58;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"in vivo animal studies (not regarding results from cats or goats): oral absorption: - rats: 85 – 86 % of radiolabel were detected in urine within 24 hr after single oral doses of [14C]-OPP (ref.: 9; 227; 243). - male b6c3f1 mice: within 24 hr after a single oral dose of [14C]-OPP at 15 or 800 mg/kg bw, 90 % of the radiolabel was found in urine (ref.: 9;159). - dogs: 45 – 57 % absorption in oral single dose studies; 45 – 54 % absorption in oral repeat dose studies (ref.: calEPA, 2007). distribution - f344 rats: radiolabel after single gavage administration of [14C]-OPP and [14C]-SOPP amounted to < 8 % at 24 hr and < 1 % at 7 days. tissues examined were adipose tissue, intestine, liver, kidneys, blood, urinary bladder, stomach, brain. I.e. accumulation of parents and/or metabolites is not expected (ref.: 243). - beagle dogs: after gavage administration of [14C]-OPP, radiolabel was detected in decreasing amounts in the following tissues: liver, lung, kidneys, bile, brain, heart, spleen. the amount of radiolabel in liver, brain, and lung remained the highest 120 hr after dosing (ref.: 223). metabolism: the major metabolite of OPP is the sulfate conjugate of the parent compound (OPP-S). the corresponding glucuronide conjugate (OPP-G) was found at lower levels, except at the high dose of 924 mg/kg (via diet). lower levels of the hydroxylated metabolite 2- phenylhydroquinone (PHQ) were observed as the glucuronide and sulfate conjugates (PHQG and PHQ-S, respectively). low levels of another ring-hydroxylated product (2,4'dihydroxybiphenyl) were seen as the sulfate conjugate (DHB-S). 2-phenyl-1,4- benzoquinone (PBQ) has been found as an oxidative metabolite of OPP. this metabolite has been postulated to be involved in the formation of bladder tumours in rats. an overview on the amounts of OPP metabolites formed in oral animal studies of different duration and administration is given in the table (m. bartels, response to calEPA report). OPP metabolites in free form were only found to a minor extent in urine. a sex difference of urinary metabolites was observed in that male rats produced much more PHQ glucuronidethan females within 24 hr. in a feeding study with SOPP it could be demonstrated thatlevels of free OPP, PHQ and PBQ increased with increasing dose. overall, when combined with information obtained from humans, it can be concluded that metabolism of OPP is quite similar in rats, mice and humans.excretion- rats: the majority of the absorbed OPP is excreted via urine (about 85 %) but excretion also occurs via bile: after an oral dose of [14C]-SOPP a higher amount of radioactivityoccurred in the bile (26%) compared to faeces (4%) of male f344 rats .(ref.: 9; 227; 243)- mice: recovery of radiolabel in the urine was about 90% at 24 hours after a single dose of[14C]-OPP (15 or 800 mg/kg bw); the radiolabel recovered in the faeces was about 9%within 48 hours (only this time point was measured) (ref.: 9) ";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
β-arbutin;;http://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_169.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"in vitro studies: hepatic metabolism:with respect to hepatic metabolism in vitro experiments demonstrated that incubation ofOPP with rat liver microsomes produced phenylhydroquinone (PHQ) andphenylbenzoquinone (PBQ). it was proposed that OPP is sequentially oxidized: first to PHQ then via an intermediate PHQ-semiquinone radical (PSQ) to PBQ, with superoxide anion (O.-) as a co-product; further, a redox recycling between PHQ and PBQ in which PBQ was reduced by cytochrome P-450 reductase (with NADPH as a cofactor) was proposed (ref.233). further metabolites identified by incubation with rat liver microsomes or rat hepatocytes were OPP-glucuronide (OPP-G), PHQ-glucuronide (PHQ-G), OPP-sulfate (OPPS), and PHQ-GSH conjugate, the latter formed by a non-enzymatic pathway. sulfation was a more important phase II reaction of OPP than glucuronidation at low concentrations (e.g.7 μM) whereas the reverse was true at the high concentration (e.g.50 μM). the dose dependent shift in the phase II metabolism may have been due to the saturation of phenolsulfotransferase rather than the depletion of substrate (ref. 186; 309; koster et al.,1981).based on the hypothesis that prostaglandin H synthase (PHS) localised in the transitionalepithelium of rat urinary bladder and rat kidney medullary papilla might be responsible for activation of PHQ in bladder and kidney, it could be demonstrated that PHQ was co-oxidisedwith arachidonic acid (ARA) by PHS, with PBQ as a reaction product (ref.: 142).the underlying hypothesis, however, was questioned by additional studies that demonstrated that PHS only poorly oxidised OPP and by studies that did not provide evidence for an ARA-dependent, PHS-catalysed formation of genotoxic species from PHQ(ref. 3). further, OPP, PHQ, and PBQ inhibited the activity of PHS-cyclooxygenase andtherefore, the ARA-mediated PHQ-oxidation. it was argued that considerable inhibition ofPHS-cyclooxygenase could occur in vivo (ref 48). as prostaglandins possess anti-ulcerativeand cytoprotective properties, PHS inhibition might be the cause for reduced cytoprotection.however, it is currently unclear whether sufficient amounts of free OPP or PHQ are presentin the bladder to achieve reduced cytoprotection.nonenzymatic metabolism: it could be further shown, that PHQ can be converted to PBQ by non-enzymatic autoxidationin vitro which is able to address a lot of issues in SOPP/OPP induced bladder tumour formation, i.e. the higher potency of SOPP when compared to OPP and sex- and strainspecific differences in bladder tumour formation (ref.: 144). a pH-dependent/oxygenindependent PHQ autoxidation most probably plays a greater role in body fluids of low oxygen tension such as urine. in this pH-dependent pathway PHQ oxidation occurs via formation of a phenylhydroquinone semichinone radical (PSQ) and formation increases with increasing pH. as sufficient amounts of free PHQ in urine are required for this pathway tooccur, it has been hypothesised that bladder tumour formation in rats is dependent on different factors that favour the formulation of a threshold mechanism:(i) presence of significant amounts of free phenylhydroquinone (PHQ) in urine(ii) an enhanced production of a reactive species by a pH-dependent autoxidation ofPHQ(iii) sufficient residence time of PHQ in the bladder for significant quantities ofreactive species to be formed.predicted rates of PSQ correlated well with data on papillary or nodular hyperplasia in ratbladder. important to note is that SOPP caused higher alkalinity in urine compared to OPP.it was hypothesized that a urinary pH around 6 as observed in mice treated with OPP couldexplain insensitivity of this strain to OPP induced bladder cancer. with respect to sex differences, a demand of higher pH in urine to form sufficient amounts of reactive metabolites has been formulated for the female rat";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
trisodium nitrilotriacetat;non OECD;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_046.pdf;urinary excretion accounted for 54% and excretion via faeces for 27% of the applied dose. 81% - 87% of the administered dose was excreted during the study period while 4.2% - 9.5% remained in the carcass. In urine 2 major metabolites were observed and the largest peak was identified as N,N-diacetyl-toluene-2,5-diamine.;;4.2-9.5%;81-87%;;;;7;;;98.2 (radiochemical purity) and 98.3(non-labelled);;CFQ13783, batch 1 [ring-U-14C]- toluene-2,5-diamine sulfate and 2346 (non-labelled);toluene-2,5-diamine sulfate;[ring-U-14C]- toluene-2,5-diamine sulfate;;rat/wistar kyoto WKY/NR Crl BR (inbred);;;f;;4 animals (mass balance), 6 animals (kinetics);;2.5 mg/kg bw;single application;yes ;;;;;urine and faeces;"0-8, 8-24, 24-48,
48-72, 72-96 h intervals";water;;;yes;59;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;in labratory animals, dermal absorption of a hair dye formulation in rat. the percutaneous absorption of radio labelled 14C-n,n’-bis-(2-hydroxyethyl)-2-nitropphenylenediamine was studied in rats(sprague dawley rats (him:ofa) 5 males and 5 females in each of 2 experiments) after 30 minutes application of a formulation to the back skin containing [14C]-labelled n,n’-bis-(2-hydroxyethyl)-2-nitro-p-phenylenediamine 1%, water 84.75%, solvents 5%, detergents and emulsifiers 7.5%, ammonia 0.25% and other vehicle constituents 2.5%. (method: 14C ring labelled n,n’-bis-(2-hydroxyethyl)-2-nitro-p-phenylenediamine in a hair dye formulation (without developer), radiochemical purity > 98%, applied to the back skin for 30 minutes and then rinsed off/ test substance: 1% radio labelled n,n’-bis-(2 -hydroxyethyl)-2-nitro-pphenylenediamine in a hair dye formulation) the formulation was spread on shaved dorsal skin until wetted. the mean mass of test substance applied was 1.06-1.08 mg/cm². removed by shampooing and rinsing and the rinsings collected. test area was covered with gauze to prevent licking. the detection limit for radioactivity from the various samples from the cutaneous application experiments was ≤ 0.01% of applied 14C. experiment a: faeces and urine were collected daily for analysis. after 72 hours the animals were sacrificed and the treated skin as well as the carcass were analysed for remaining radioactivity. experiment b: blood was drawn at 35 minutes, 1, 2, 4, 8 and 24 hours, the animals were sacrificed and 13 organs and carcass analysed for remaining radioactivity. mass balance was calculated. further, two experiments were performed with peroral dosing. one animal died before end of study. the mean percutaneous absorption of the test substance was 0.22% of applied 14C equivalent to 2.37 μg/cm2 test substance. n,n’-bis-(2- hydroxyethyl)- 2-nitro-p-phenylenediamine was excreted mainly via urine (67%) and to a lesser extent via faeces (33%). the excretion was fast with 81% eliminated within the first 24 hours. the mass balance in experiment a gave a recovery of 99.4% of 14C doses from the various samples. the blood level after cutaneous application was highest at the first sampling time at 35 minutes (mean 0.000129% ± 0.000061%) and with a half-life of 0.7 hours. after 24 hours the 14C content in the organs was below or near detection limit. the highest concentration of 14C was found in ovaries, thyroids, blood, liver and kidney. there was no measured retention in any tissue except in the treated skin after 24 and 72 hours. an oral dose study in rats found the highest organ concentrations after 24 hours in kidneys, liver, adrenals and thyroid. although the concentrations after cutaneous application are close to the detection limit and conclusions therefore restricted, it seems that the distribution pattern is similar after cutaneous and oral application of test substance.;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
toluene-2,5-diamine and its sulfate;/;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_052.pdf;oral absorption of toluene-2,5-diamine sulfate was rapid with Tmax values of 1 h. AUCs were 8.53 (low dose) and 112 mgeq x h/l (high dose).;;69;;;;;7;;;99.3% (radiochemical purity) and 98.3% (non-labelled toluene-2,5-diamine sulfate);;3362-259 [ring-U-14C]- toluene-2,5-diamine sulfate CFQ13783, batch 1 [ring-U-14C]- toluene-2,5-diamine sulfate and 2346 (non-labelled toluene-2,5-diamine sulfate);toluene-2,5-diamine sulfate;[ring-U-14C]- toluene-2,5-diamine sulfate;;rat/sprague-dawley Crl:CD (outbred);;;f;;6 animals;;2.5, 25 mg/kg bw;;;yes, gavage ;;;;blood;" 0.25, 0.5, 1, 2, 4, 6,
24, 48 and 72 h";water;;;yes;60;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;bioavailability across the intestinal barrier. cells: human intestinal epithelial cell line tc-7, a sub-clone of the caco2 cell line. test substance: hydroxyethyl-p-phenylenediamine sulfate (betoxol II). batch: 36/37. purity: ~99.8%. concentration: 50 µM in hbss buffer containing 1 % dmso.incubation time: 60 min. number of experiments: two independent experiments. glp: not in compliance but QAU checked. study period: 4 pril – 2 may 2005. the bioavailability of hydroxyethyl-p-phenylenediamine sulfate across the intestinal barrier was investigated in human intestinal epithelial (tc-7) cells in vitro. the permeability from the apical (A, pH 6.5) to the basolateral (B, pH 7.4) side was investigated at 37° C in 96- well multiscreen plates with shaking for a 60 min contact time. analysis of the donor (apical) and receiver (basolateral) samples was done by means of HPLC-MS/MS, and the apparent permeability coefficient (Papp) was calculated for two independent experiments. 14C-mannitol (4 µM) was used to demonstrate the integrity of the cell monolayer. only monolayers with a mannitol permeability of < 2.5 x 10^-6 cm/sec were used. propranolol and ranitidine were used to validate the experimental conditions. according to the laboratory’s classification system, a low permeability is considered for test items revealing a Papp < 2 x 10^-6 cm/sec. a Papp of 2 - 20 x 10^-6 cm/sec and a Papp ≥ 20 x 10^-6 cm/sec classify a substance to have a medium or a high permeability, respectively. ranitidine, which has a 50 % absorption in humans, was used as low permeability reference compound, as recommended by fda. the figures for the reference substances propranolol (Papp = 53.1 x 10^-6 cm/sec), a high permeability reference compound with about 100 % absorption in humans, and ranitidine (Papp = 0.17 x 10^-6 cm/sec) revealing an absorption of about 50 % in humans, were well within the typical range of 20 – 60 x 10^-6 cm/sec and < 2 x 10^-6 cm/sec, respectively. hydroxyethyl-p-phenylenediamine sulfate revealed a Papp of 77.5 x 10^-6 cm/sec and thus was classified to be of high permeability, indicating a nearly 100 % absorption from the gastro-intestinal tract. as the absorption from the gastro-intestinal tract is likely to be permeability limited, the high permeability observed in this assay indicates a good absorption hydroxyethyl-p-phenylenediamine sulfate after oral administration. ref.: 31;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
toluene-2,5-diamine and its sulfate;/;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_052.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;species/strain: sprague dawley rats. group size: 3 males and 3 females per group. method: urine and faeces excretion, carcass and organs analysis after topical application and oral administration by gavage. test substance: hydroxyethyl-p-phenylenediamine sulfate (radiolabelled 14C) in commercial formulations with and without hydrogen peroxide 1.47%. reference: hydroxyethyl-p-phenylenediamine sulfate (radiolabelled 14C) in water 4.88%. dose levels: 1.63 mg/cm² for the formulations with or without hydrogen peroxide (total area treated 9 cm²) 1.67 mg/cm² for the aqueous solution (total area treated 9 cm²) 3 mg for the aqueous solution (0.3 %) administered orally by gavage. contact duration: 30 minutes, then washing of the skin and monitoring of the diffusion during 72 hours. analysis: liquid crystal scintillation. glp: in compliance. the experimental variability is very high. the mean percutaneous absorption in vivo calculated from the excretion and residual amounts in the carcass is low: 0.063 ± 0.063% of the dose when the substance is applied without hydrogen peroxide, and 0.077 ± 0.074% of the dose when the substance is applied with hydrogen peroxide. this is corresponding to 1.03 to 1.26 μg/cm². for the aqueous solution, the amount absorbed is 0.124 ± 0.097% of the applied dose (2.07 μg/cm²). the radioactivity was excreted predominantly via urine (75 to 86 %) than via the faeces (14 to 25%). after topical application, the concentrations in the organs were near the detection limit (thyroids, adrenals, brain, testes, bones). after oral administration the test substance is excreted via urine (86 %) and to a less extent via faeces (14%). highest concentrations were obtained in thyroids, liver and adrenal. lowest were detected in the testes, fat and femur. when considering the residual amount of material present in the skin at 72 hours, the total amount absorbed corresponds to 15 μg/cm² for the formulation without hydrogen peroxide or to 35 μg/cm² with hydrogen peroxide. for the aqueous solution, the absorption is equivalent to 7.5 μg/cm². these data show clearly the influence of the formulation on the absorption of the dye. ref.: 32;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
toluene-2,5-diamine and its sulfate;417;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_052.pdf;radioactivity in plasma was eliminated with a half-life of 28.3 h.;;;;;;;7;;;98.2%(radiochemical purity) and 98.3%(non-labelled toluene-2,5-diamine sulfate);;CFQ13783, batch 1 [ring-U-14C]- toluene-2,5-diamine sulfate, 2346 (non-labelled toluene-2,5-diamine sulfate);;[ring-U-14C]- toluene-2,5-diamine sulfate;;rat/sprague-dawley Crl:CD (outbred);;;f;;6 animals;;2.5 mg/kg bw;single application;yes;;;;;blood;"5, 15, and 30 min and 1,
2, 4, 6, 24, and 48 h ";water;;;yes;61;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;liquid scintillation counting;mean recovery of the applied test material (mass balance) was 82.4% of the applied dose. the mean systemically available dose of HEPB sum of amounts measured in living epidermis/dermis and receptor fluid after application of a typical skin care formulation containing this preservative ingredient at 2% was estimated to be 36.8±17% of the applied dose (16.0±7.4 μg equiv/cm²). the applicant concluded that the mean recovery rate of 82.4% of the applied dose obtained in this study was a bit low. however, similar to greater losses of radioactivity were obtained in a dedicated study evaluating the recovery rate of [14C]-HEBP 24 hours after simple spiking (craig, 2014b). therefore it was concluded that the low recovery rate obtained in the in vitro percutaneous absorption study would not put the scientific validity of this study into question. ;36.8;;;;;;2;"radiodiluted [14C]-r0069279a in a cosmetic formulation; 104.2 % of target, a typical lipophilic skin care formulation ";"96.0 ± 1.3 % (non-labelled material); 98.0  (labelled material; radiochemical purity)";;"r0069279a 019 d 004 (non-labelled material); cfq41364 (labelled material)";"test substance: r0069279a (non-labelled); [14C]-r0069279a (labelled)";;;human split-thickness abdomen skin from 4 donors aged 30 – 63 years and one split-thickness breast skin sample from a female donor aged 58 years ;after 24 hours of exposure, the skin surface was rinsed-off;;5/12;static diffusion cells;calcium- and magnesium-free phosphate buffered saline (PBS) containing bovine serum albumin (5%, w/v);;membrane integrity: sample exhibiting a resistance < 4 kΩ excluded, mass balance provided,  24 hours after application, the stratum corneum was removed by 20 tape strippings and the penetration, mass balance and distribution of [14C]-HEPB were determined by measuring its concentration in relevant compartments (e.g. skin wash, epidermis, dermis, and receptor fluid);;;;3.14 ;2.11 ;24 hours after application;24h;2012;the dedicated study evaluating the recovery rate did not provide any explanation for the low recovery. as HEPB possesses a low vapour pressure, evaporation appears unlikely. nevertheless, in order to avoid loss, occlusive conditions could be used in dermal absorption studies. according to SCCS 1358/10, recovery should be at least 85%. a recovery of at least 85% was only obtained for 4 cells evaluated. eliminating all other cells leads to only 4 evaluable cells from 2 different donors, which is not in line with SCCS 1358/10. the chosen cut-off value of 4 kΩ for barrier function assessment is not of common practice (threshold of 10 kΩ is normally used) and may lead to an overestimation of the results. SCCS notes that dermal penetration was only investigated using a cosmetic formulation consisting of 93% of an oily phase and 7 % of water phase. appropriate studies should be performed for the intended uses in representative cosmetic formulations. based on significant deviations from requirements, the SCCS considers the study unacceptable. instead, in the absence of adequate experimental data, a default value of 50% dermal absorption is taken for MoS calculation according to SCCS 1564/15. ;7, 8;yes;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
toluene-2,5-diamine and its sulfate;427;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_052.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"in vitro, test substance: r0069279a, glp: yes, study period: 2014. in each experiment and if applicable, the respective reference compounds (propranolol: highly permeable; labetalol: moderately permeable; ranitidine: poorly permeable; colchicine: p-glycoprotein substrate) were tested concurrently with HEPB, and the data were compared with historical values determined at the testing facility. only limited information was provided on the experimental setting. the apical-basolateral (A-B) permeability of HEPB in human intestinal epithelial caco-2 cells (pH 6.5/7.4) was determined and compared to that of the reference compounds. test concentration of 10 µM HEPB (batch: 019 p 001) was used. result: test item has a mean apparent permeability coefficient of 62.2 x 10^-6 cm/s. based on this result of the test item and the reference compounds, the test item should be highly permeable. SCCS comment: the study report is extremely poor. however, it can be inferred from the results of the study that penetration of HEPB through the caco-2 monolayer is high. ref.: 9";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
toluene-2,5-diamine and its sulfate;417;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_052.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;the plasma toxicokinetic profile of hc yellow n° 9 was investigated after single oral administration (gavage) to cd1 mice. given the aim of the present study, the experimental conditions used (animal species, strain, age, dose-level, route, vehicle, dosage volume, dosage form preparation) were similar to those used in the mouse micronucleus test. twenty-four male and twenty-four female cd1 mice (about 6 weeks old) were placed into a single group and were treated once by oral administration (gavage) with the test item, hc yellow n° 9 at the dose level 100 mg/kg bw. the test item was given as a suspension in 0.5% carboxymethylcellulose in a volume of 10 ml/kg. blood samples were collected from the animals (three animals/sex/time point) as follows: 0, 0.25, 0.5, 1, 2, 3, 4, 8 and 24 hours, post-gavage. the plasma was analysed for test item levels by a hplc/uv method. following oral administration of the test item at a nominal dose level of 100 mg/kg in 0.5% carboxymethylcellulose (at 10 ml/kg) to cd1 mice, the mean (n = 3) (± standard deviation) plasma levels increased quickly to a maximum (Cmax) at 0.25 hour (tmax) postgavage (2.36 ± 0.71 and 3.2 ± 1.62 μg/mL for males and females, respectively). thereafter, levels decreased in a regular manner until the last quantifiable time-point at 4 hours for both sexes (0.385 ± 0.13 and 0.230 ± 0.22 μg/mL for males and females, respectively). the limit of quantification was 0.2 μg/ml. exposure to the test item, as estimated by the areas under the curve (AUC0-t and AUC0-∞), calculated using the loglinear trapezoidal rule (non-compartmental pharmacokinetics), were 3.02 and 4.08 μg/ml*h, respectively, for males and 3.79 and 4.18 μg/ml*h, respectively, for females (% of AUC extrapolated ≥ 20%). the terminal half-life (t1/2z), was 1.90 h for males and 1. 18 h for females. the study showed that the animals were systemically exposed to hc yellow n° 9 following oral administration at the dose level 100 mg/kg bw in 0.5% carboxymethylcellulose. the test item was above quantifiable limits (0.2 µg/mL) in the plasma until 4 hours post-dosing for both sexes, the plasma levels were characterized by a fast absorption phase and the Cmax was reached at 0.25 hour post-gavage. ref.: 11 (subm. 3) ;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
toluene-2,5-diamine and its sulfate;417;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_052.pdf;highest mean observed concentration (Cmax) was similar for both males and females and increased proportionally with an increase in dose. Cmax was observed between 0.40 and 0.60 h post dose, suggesting a rapid absorption of the test material following the oral dose. plasma radioactivity concentrations declined but were still detectable at 72 h post dose for both groups. systemic exposure based on AUC(0-∞) was slightly higher for females as compared to males and increased proportionally with an increase in dose. mean terminal elimination half life (T1/2) was similar for both sexes and ranged from 11.3 to 14.2 h.;;;;;;;5.0 +/- 0.3;;;98.9 [ring-14C(U)]-toluene-2,5-diamine sulfate and non-radiolabelled toluene-2,5-diamine sulfate: 99.5;;CFQ40808, Batch B1- [ring-14C(U)]-toluene-2,5-diamine sulfate and  R0022279 – (Non-radiolabelled toluene-2,5-diamine sulfate);;[ring-14C(U)]-toluene-2,5-diamine sulfate;;rat/sprague-dawley;;;f & m;;12;;5 mg/kg and 10 mg/kg (containing approximately 100 µCi of radioactivity per dose);single administration;;yes, gavage ;;;;blood;"0.25, 0.5, 1, 2, 4, 8, 24,
48, and 72 h";reverse osmosis deionized water;male and female animals (6 per sex per dose) were administered an oral gavage dose of [14C]-toluene-2-5-diamine sulfate. Blood samples were collected at regular intervals over a 72-hour period, and radioactivity was measured in plasma. Toxicokinetic parameters including AUC(0-∞) were calculated from the plasma concentration versus time profiles.Toluene-2,5-diamine sulfate was rapidly absorbed following an oral dose, with a Tmax of approximately 0.5 hr. Cmax values corresponding to a dose of 10 mg/kg bw were 12.6 + 1.11 μgeq x h/ml and 13.3 + 0.984 μgeq x h/ml in males and females, respectively. Mean plasma AUC(0-∞) values corresponding to a dose of 10 mg/kg bw were 41.0 + 3.30 μgeq x h/ml and 51.6 μgeq x h/ml in males and females, respectively. The overall mean plasma AUC(0-∞) for males and females combined was 46.3 μgeq x h/ml, and this value was used by the applicant in the proposed toxicokinetics based MoS calculation.;2010;yes;14 (subm III);;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;in vitro. the bioavailability of hc yellow n° 13 (batch: 97/92/1094, purity: 99.9 area%)(test concentration: 10 µM in hbss buffer containing 1 % dmso) across the intestinal barrier was investigated in human intestinal epithelial (tc-7) cells in vitro in 2 independent experiments. permeability from the apical (a, pH 6.5) to the basolateral (b, pH 7.4) side was investigated at 37 °C in 96-well transwell plates with shaking for a 60 min contact time. analysis was done by means of hplc-ms/ms and the apparent permeability coefficient (Papp) was calculated for two independent experiments. only monolayers revealing a permeability of < 2.5 x 10^-6 cm/sec were used. according to the laboratory’s classification system, a low permeability is considered for test items revealing a Papp < 2 x 10^-6 cm/sec. a Papp of 2 - 20 x 10^-6 cm/sec and a Papp ≥ 20 x 10^-6 cm/sec classify a substance to have a moderate and a high permeability, respectively. total recovery for the reference substances and hc yellow n° 13 ranged from 73 to 162 %. for hc yellow n° 13 a Papp of 82.6 x 10^-6 cm/sec (86.7 and 78.5 x 10-6 cm/sec) was determined and thus the test substance was classified to be of high permeability, indicating a good absorption from the gastrointestinal tract. a mean permeability in human intestinal epithelial (tc-7) cells of 82.6 x 10^-6 cm/sec was obtained with HC Yellow n° 13 which classifies the test item to be of high permeability. as the absorption across the intestinal epithelium is considered to be the limiting factor of the uptake through the gastro-intestinal tract, the high permeability observed in this assay indicates agood absorption of hc yellow n° 13 after oral administration. ref.: 30. the study was not performed under glp conditions, but a statement of the quality assurance unit of the test facility is included. there is no official guideline for this assay.however, the study was performed according to ECVAM recommendations. the generated data is considered to provide an estimation of the bioavailability of hc yellow n° 13 after oral administration. ;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
toluene-2,5-diamine and its sulfate;427;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_052.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"in vivo study in rats. species: rat/ sprague dawley him: ofa; group sizes: 3 males and 3 females; route: topical and oral; material: 14C- hc yellow n° 13 at 2.5 % in formulations with and without hydrogen peroxide, and in water/dmso (1:2); batch: az2Ì2; purity: 99.8 % (hplc at 210 nm); application route: experiments a, b, c: dermal; experiments d, e: oral; dose levels: exp. a: formulation without H2O2: 2.5 %; 2.23 mg/cm²; exp. b: formulation with H2O2; 2.5 %; 2.72 mg/cm²; exp. c: solution in water/dmso (1:2); 8.33 %; 2.85 mg/cm²; exp. d: solution in water/dmso (1:2); 2.5 %; 122.2 mg/kg bw; exp, e: solution in water/dmso (1:2); 2.5 %; 127.1 mg/kg bw; treatment: exp. a, b, c: single dermal application for 30 min; exp. d, e: single oral administration (gavage); glp: in compliance. dermal application (experiments a, b and c)14C- hc yellow n° 13 was applied dermally to groups of 3 male and 3 female rats (body weight about 200 g). the application area was 9 cm2 and the test substance was applied at concentrations of 8.33 % in solution (water/dmso 1:2, experiment c) and of 2.5 % informulations without (experiment a) and with hydrogen peroxide (experiment b) for 30 min. the mean amount of the applied dyestuff corresponded to 9.68, 2.90 and 2.51 µg/cm2,respectively. after treatment the test substance was scraped off and the skin rinsed with a shampoo formulation followed by water until the rinsing water was free from colour. rinsing solutions were collected. during the exposure time, animals were constrained to avoid licking. after rinsing, the area was covered with gauze fixed by adhesive tape and an additional air permeable plastic cone to further prevent licking of the treated area during the 72 ħ in themetabolism cages. oral administration (d and e):5 mg/kg bw, 14C- hc yellow n° 13 was administered as a 2.5 % solution in water/dmso 2:1 by gavage to two groups of 3 male and 3 female rats each which were starved for 16 hours before treatment. in experiment d animals were placed in metabolism cages for 72 h. in experiment e, blood was taken at several time points within 24 h after administration. during the studies, blood was taken from the retrobulbar venous plexusunder light ether anaesthesia. at termination of the experiment, blood samples were taken from the aorta.urine and faeces were collected daily (0-24, 24-48 and 48-72 h after administration) from the metabolism cages. animals were killed 72 hours (a, b, c, and d) and 24 hours (e) after the application and the application sites (a, b and c) as well as some organs were taken and analysed for radioactivity. the radioactivity in the remaining carcass after skin removal (a, b, c and d) or removal of the gastro-intestinal tract (d) was also determined. results: total recovery of the applied radioactivity for the individual animals in the experimentsranged from 98.0 to 99.2 % in the dermal groups and 98.73 % in the oral group d. the 14C-content of the gastro-intestinal tract in experiment d was not determined. dermal application seventy two hours after application, the amount of radioactivity remaining at the applicationsite (skin) was less than 0.15 % for all three experiments. The highest value (0.15 % of theapplied dose) was noted for the formulation with hydrogen peroxide (experiment B). For theformulation without H2O2 (A) and with the DMSO/water solution (C), the figures were 0.121and 0.146 %. The majority of the dyestuff was removed by rinsing 30 min after theapplication. 97.8 to 98.68 % of the applied dose was found in the washing water.0.128 %, 0.091 % and 0.336 % of the applied doses were eliminated via urine and faeceswithin 72 h in experiment A, B and C, respectively. The lowest absorption rate was obtainedfor the formulation containing H2O2. Radioactivity was mainly excreted via urine (63 - 75 % ofthe amounts eliminated, equal to 62 - 74 % of the amounts absorbed) and to a lowerextent via faeces (25-37 % of the amounts eliminated). 81 - 89 % of the total amounteliminated was excreted within the first 24 hours.The radioactivity remaining in the carcass (0.0024 to 0.0033 % of the administered and 1.0to 1.8 % of the adsorbed dose) was below or near the detection limit in experiments A, B andC. Residues in organs were mostly below the detection limit, with highest concentrations notedfor thyroids, adrenals and fat.Based on these results, the amount cutaneously absorbed was 0.121 % (equal to 2.90 µg/cm2)for the formulation without H2O2, 0.15 % (equal to 2.50 µg/cm2) for the formulation with H2O2and 0.147 % (equal to 9.68 µg/cm2) for the pure dyestuff in water/dmso. oral application: after oral application, 14C- hc yellow n° 13 was mainly eliminated via urine (82 % of the applieddose within 72 h) and to a minor extent via the faeces (1 %). elimination was fast as themain part was excreted within the first 24 hours (87 %). the radioactivity found in tissues 72h after administration was generally very low (less than 0.003 % of the applied dose per gorgan), with higher values noted in fat, liver and skin. in experiment r the blood level reached a peak at 120 min after application and declined with an initial half-life of 1 h. conclusion: hc yellow n° 13 given orally to rats is quickly absorbed and excreted within 72 h, with themajority eliminated within 24 h after application. excretion takes place predominantly (82 %) via urine and to a minor extent via faeces, demonstrating a good bioavailability after oral application, which is in line with findings obtained in vitro. the observed excretion pattern after dermal application is similar to the one observed for the oral route, with the majority excreted via urine within 24 hours after administration. the amount cutaneously absorbed was 0.121 % (equal to 2.90 µg/cm²) for the formulation without H2O2, 0.15 % (equal to 2.50 µg/cm²) for the formulation with H2O2 and 0.147 % (equal to 9.68 µg/cm²) in water/dmso. low tissue residue levels were noted for both routes of exposure (dermal or oral), indicating that bio-accumulation would not be expected. the remaining radioactivity in the skin after dermal application was also low (less than 1 % of the applied
dose). ref.: 31 ";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
toluene-2,5-diamine and its sulfate;417;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_052.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"toxicokinetics after oral dosing. species/strain: rat, wistar han. group size: group 1, plasma kinetics: 9 males, 9 females group 2, excretion: 3 males, 3 females. test substance: 14C-imexine oax, c6666 ag [U-Ring-14C]. batch: lot 98218a. purity >97%. dose: 100 mg/kg bw (1.85 MBq/kg), gavage. observation period: group 1: 1 – 72 h post-gavage. group 2: daily until 168 h post-gavage. glp: statement included. a single dose of the test substance (100 mg/kg bw; gavage) was applied to 9 male and 9 female rats in group 1 (plasma pharmacokinetics) and to 3 males and 3 females in group 2 (excretion balance). in group 1 blood samples were collected at 1, 2, 4, 6, 8, 24, and 72 hours post-gavage. in group 2 urine, faeces and cage-wash were collected pre-dose, and then daily until 168 hours post-gavage; organs/tissues were not analysed as the radioactivity was almost completely eliminated within test period. results. only a small fraction of the test substance was absorbed; absorption based on data for urine excretion plus cage wash was 5.3% of the applied dose (2.6 – 14.7 %). the test substance, however, was rapidly absorbed (plasma Cmax was reached after 1-2 h). the excretion was rapid and almost complete (t1/2 1.9 h and 2.3 h in males and females, respectively). the radioactivity was mainly eliminated via faeces (>70% within 24 h). the total excretion for urine and faeces were 2.5 and 95.4%, respectively, for males and 3.7 and 88.6 %, respectively, for females. ref.: 22. comment on bioavailabiliy: from the toxicokinetics study after oral dosing, an oral absorption rate of 5.3%, based on urinary excretion, may be deduced. ";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
toluene-2,5-diamine and its sulfate;/;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_052.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"toxicokinetics after cutaneous application. species/strain: rat, wistar han. group size: group 1, plasma kinetics: 9 males, 9 females group 2, excretion: 3 males, 3 females. test substance: 14C-imexine oax, c 6666 ag [U-Ring-14C]. batch: lot 98218A. purity: 98.4%. dose: 25 mg/kg bw in water (2.2 MBq/kg), 30 min, over 10% of body surface area. observation period: group 1: 1 – 72 h post-application group 2: daily until 168 h post-application. GLP: statement included. study date: september 1999. a single dose of the test substance (25 mg/kg bw) was applied to 9 male and 9 female rats in group 1 (plasma pharmacokinetics) and to 3 males and 3 females in group 2 (excretion balance). in group 1 blood samples were collected at 1, 2, 4, 6, 8, 24, and 72 hours postapplication. in group 2 urine, faeces and cage-wash were collected pre-dose, and then daily until 168 hours post-application; organs/tissues were not analysed as the radioactivity was almost completely eliminated within test period. results. following topical application (25 mg/kg bw, 30 min) the radioactivity in all plasma samples was below quantifiable limits (80% within 72 h). ref.: 23. the amount (%) of the applied dose that may be considered as being systemically available (urine, faeces, cage wash and that remaining in stripped skin) was 0.643 ± 0.24% (range 0.488 – 0.92%) in the male rats and 0.579 ± 0.082 (range 0.498 – 0.663%) in the female rats. the mean of the six experiments was 0.61 ± 0.16%. comment on bioavailability: the data of the toxicokinetics study after dermal application, on the other hand, demonstrate a considerable proportion of biliary excretion. a complete kinetic study after multiple oral doses and data on possible metabolites are not available. the sccs therefore assumes 10 % oral bioavailability as worst case.";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
toluene-2,5-diamine and its sulfate;427;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_052.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
toluene-2,5-diamine and its sulfate;417;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_052.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
sodium perborate;;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_031.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
phenylene bis-diphenyltriazine;;https://ec.europa.eu/health/sites/health/files/scientific_committees/consumer_safety/docs/sccs_o_215.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
methylimidazoliumpropyl p-phenylenediamine HCl ;non OECD;https://ec.europa.eu/health/sites/health/files/scientific_committees/consumer_safety/docs/sccs_o_231.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
methylimidazoliumpropyl p-phenylenediamine HCl ;428;https://ec.europa.eu/health/sites/health/files/scientific_committees/consumer_safety/docs/sccs_o_231.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"permeability of 1-hexyl-1H-pyrazole-4,5- diamine hemisulfate through human intestinal epithelial caco-2 cell line layers. the permeability from the apical (A, pH 6.5) to the basolateral (B, pH 7.4) side was investigated at 37 °C in 24-well plates with orbital shaking for 4 hours. [ring 14C] 1-hexyl-1H-pyrazole-4,5-diamine hemisulfate (batch no: cfq41662, radiochemical purity: 98.4 %)  was prepared at a concentration of 10 µg/ml in dulbecco’s phosphate buffered saline (dpbs). cells in transwells were allowed to acclimatise in an incubator for 30 minutes prior to the addition of 1-hexyl-1H-pyrazole-4,5-diamine hemisulfate or the reference chemicals, mannitol, propranolol and ranitidine. trans-epithelial electrical resistance (TEER) was measured prior to and after the 4-hour incubation with test and reference chemicals. incubations were performed in triplicate. sampling time points were 60, 120, 180 and 240 minutes post-dose. analysis of the donor (apical) and receiver (basolateral) samples was by liquid scintillation counting, apart from ranitidine samples, which were analysed by hplc-ms/ms. the kp of 1-hexyl-1H-pyrazole-4,5-diamine hemisulfate was 12.0 x 10-4 cm/minute. there was a slight decrease in the TEER values over the course of theincubation which may show a slight affect from the test substance; however, at the end of the study the TEER values were still above what is typically considered an acceptable TEER value (300 Ohms*cm2) and the decrease was not considered to have affected the permeability value measured in this study. the kp for the low permeable reference compound, ranitidine, was 0.3 x 10-4 cm/minute and was within the acceptable permeability range for this compound (0.12 - 1.2 x 10-4 cm/minute). the mannitol kp was 1.1 x 10-4 cm/minute and was an acceptable rate for this compound (<1.5 x 10-4 cm/minute), indicating that the caco-2 monolayer was intact with functioning tight junctions. the kp for the highly permeable reference compound, propranolol was 14.4 x 10-4 cm/minute and was within the acceptable permeability range for this compound (12.0 –27.0 x 10-4 cm/minute). the permeability constant (kp) obtained for 1-hexyl-1H-pyrazole-4,5-diamine hemisulfate indicates that it is considered to be moderately to highly absorbed in the human intestine. ref. 28. sccs comment: the study was not performed under glp conditions. there is no official test guideline for this assay. only one cell batch was used and 3 replicate incubations were done on the same cell batch; usually, at least 3 different cell batches are used. the generated data are considered to provide an estimation of gastrointestinal absorption of 1-hexyl 4,5-diamine pyrazole sulfate after oral administration. the substance is expected to be highly absorbed after oral administration. ";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
p-aminophenol;/;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_078.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"metabolism of 1-hexyl-1H-pyrazole-4,5-diamine hemisulfate (batch: rd-cru-096-07/142-01 (non-radiolabelled); purity: 99.1 area% (non-radiolabelled), 99% (radio-hplc))  was tested following a 3- and 24-hour incubation with cryopreserved plated human hepatocytes. 1-hexyl-1H-pyrazole-4,5-diamine hemisulfate was tested at final concentrations of 1.276, 12.76 and 127.6 μg/mL (7, 70, and 700 μM, respectively). the 7 μM solution was prepared using only radiolabelled test substance (100% radiolabelled), while the 70 and 700 μM solutions were prepared using both radiolabelled and non-radiolabelled test substance (28.6 and 2.86% radiolabelled, respectively). hepatocytes were seeded at a concentration of 350,000 cells/well (700,000 cells/ml). 7-ethoxycoumarin (1000 μM) was incubated with cells for 3 and 24 hours as a positive control to show metabolic activity (production of 7-hydroxycoumarin) in the plated hepatocytes over the entire incubation period. plated human hepatocytes were metabolically active over 24 hours in culture, as determined by the formation of 7-hydroxycoumarin at both 3 and 24 hours, which was comparable to historical data. two metabolites of 1-hexyl-1H-pyrazole-4,5-diamine hemisulfate were detected, namely n-acetyl-1-hexyl-1H-pyrazole-4,5-diamine and n-acetyl-1-hexyl-1H-pyrazole-4,5-diamine glucuronide. no parent compound was found at the 70 μM incubation after 24 hours. n-acetyl-1-hexyl-1H-pyrazole-4,5-diamine was observed in incubations with hepatocytes, at both 3 and 24 hours, and at all test concentrations. increasing the dose level of the test article from 7 to 70 to 700 μM resulted in an increase in the amount of the metabolite produced; however, the increase was not proportional to the increase in test article dosed. glucuronide was only observed in the 70 μM incubation, but was below the limit of quantification. two metabolites, n-acetyl-1-hexyl-1H-pyrazole-4,5-diamine and n-acetyl-1-hexyl-1H-pyrazole-4,5-diamine glucuronide were detected in human hepatocytes. of these, only N-acetyl-1-hexyl-1H-pyrazole-4,5-diamine was produced in quantifiable amounts. ref. 31. sccs comment: the study was not performed under glp conditions. there is no official test guideline for this assay. ";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
p-aminophenol;/;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_078.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"the metabolism of 1-hexyl-1H-pyrazole-4,5-diamine hemisulfate (batch: rd-cru-096-07/142-01 (non-radiolabelled); purity: 99.1 area% (non-radiolabelled),99% (radio-hplc) following incubation with  plated human keratinocytes (HaCaT cell line). cells were seeded at 500,000 cells/well and allowed to grow for 24 hours prior to dosing with the test article. incubations were performed in triplicate with 2.0 ml of the dosing solution for 3 or 24 hours. dosing solutions were prepared at final test article concentrations of 1.276, 12.76 and 36.45 μg/ml (7, 70 and 200 μM, respectively). samples were analysed for metabolic loss and formation of potential metabolites using an hplc-uv-rad/QToF-mass spectrometry for quantification and structure elucidation. p-aminobenzoic acid (PABA) was used as a positive control for N-acetyltransferase-1 (NAT1) enzyme by monitoring the formation of its metabolite, 4-acetamidobenzoic acid, for 3 and 24 hours. 1-hexyl-1H-pyrazole-4,5-diamine hemisulfate or PABA did not affect the growth or viability of the cells during the course of the study. one metabolite, N-acetyl-1-hexyl-1H-pyrazole-4,5-diamine, was found in the incubate samples at all three dose levels at 3 and 24 hours. increasing the dose level of the test article from 7 to 70 to 200 μM resulted in an increase in the amount of the metabolite produced at the 3 hour time point; however, the increase was not proportional to the increase in test article dosed. at the 24-hour time point, there was an increase in the amount of metabolite produced when the test article was increased from 7 to 70 μM; however, less metabolite was produced at the 200 μM test article dose level that at the 70 μM dose level. the increase was not proportional to the increase in test article dosed. no parent compound was found at the 70 μM incubation after 24 hours. PABA positive control samples showed a production of the known metabolite, 4-acetamidobenzoic acid. results indicated that the cells were metabolically active for the duration of the study. 1-hexyl-1H-pyrazole-4,5-diamine hemisulfate did not affect the growth of HaCaT cells up to a dose of up to 200 μM. one metabolite, N-acetyl-1-hexyl-1H-pyrazole-4,5-diamine was observed after incubating with HaCaT cells for 3 and 24 hours. ref. 32. sccs comment: the study was not performed under glp conditions. there is no official test guideline for this assay. ";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
p-aminophenol;/;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_078.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
p-aminophenol;/;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_078.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
p-aminophenol;/;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_078.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
p-aminophenol;/;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_078.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"biovailability across intestinal barrier in tc-7 (human intestinal epithelial) cells, guideline: / cells: human intestinal epithelial cell line tc-7, test substance: hydroxyethyl-3,4-methylenedioxyaniline HCl, batch: 9/93 fass 195, purity: 99.7 % (hplc at 254 nm), test concentration: 50 µM in hbss buffer containing 1 % dmso, incubation time: 120 min, number of experiments: two independent experiments, glp: not in compliance, but QAU-checked. the bioavailability of hydroxyethyl-3,4-methylenedioxyaniline HCl across the intestinal barrier was investigated in human intestinal epithelial (TC-7) cells in vitro. the permeability from the apical (A, pH 6.5) to the basolateral (B, pH 7.4) side was investigated at 37°C in 24-well transwell plates with shaking for a 120 min contact time. analysis of the donor (apical) and receiver (basolateral) samples was done by means of hplc-ms/ms and the apparent permeability coefficient (Papp) was calculated for two independent experiments. 14C-mannitol (about 4 µM) was used to demonstrate the integrity of the cell monolayer. only monolayer revealing a permeability of < 2.5 x 10-6 cm/sec were used. propranolol, vinblastine and ranitidine were analysed concurrently to demonstrate the validity of the test system. according to the laboratory’s classification system, a low permeability is considered for test items revealing a Papp < 2 x 10-6 cm/sec. a Papp of 2 - 20 x 10-6 cm/sec and a Papp ≥ 20 x 10- 6 cm/sec classify a substance to have a moderate and a high permeability, respectively. as recommended by FDA, ranitidine (50 % absorption in humans) was used as the low permeability reference compound and propanolol (90 % absorption in humans) was used as the high permeability reference compound. results: the total recovery for the reference substances and hydroxyethyl-3,4- methylenedioxyaniline HCl ranged from 64 to 88 %. the figures obtained for the reference substances propranolol (Papp = 34.2 x 10-6 cm/sec), a high permeability reference compound with about 90 % absorption in humans, and ranitidine (Papp = 0.3 x 10-6 cm/sec; revealing an absorption of about 50 % in humans) were well within the acceptance range of 20 - 45 x 10-6 cm/sec and 0.2 - 2 x 10-6 cm/sec, respectively, and demonstrated the validity of the assay. hydroxyethyl-3,4-methylenedioxyaniline HCl revealed a Papp of 83.1 x 10-6 cm/sec and was classified to be of high permeability. conclusion: with hydroxyethyl-3,4-methylenedioxyaniline HCl a mean permeability in human intestinal epithelial (TC-7) cells of 83.1 x 10-6 cm/sec was obtained, which classifies the test item to be of high permeability. as the absorption across the intestinal epithelial is considered to be the limiting factor for the uptake through the gastro-intestinal tract, the high permeability observed in this assay indicates very good absorption of hydroxyethyl-3,4- methylenedioxyaniline HCl after oral administration. this result is in accordance with the data obtained in the in vivo kinetic study in rats. ref: 32";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
p-aminophenol;/;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_078.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
p-aminophenol;/;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_078.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"in vivo, a single dose of hc yellow n° 7 (batch: 0509831, purity: 97.3%) in 0.5% methylcellulose  (140 mg/kg bw, dose volume: 10 ml/kg bw; oral, gavage) was administrated once to 24 male and 24 female mice (strain: of1). blood samples were collected at 0.25, 0.5, 1, 2, 4, 8, 24, and 48 hours post-gavage. plasma was analysed for test item levels by a validated hplc/uv method. no deaths and no clinical signs. two hours after dosing, all animals had orange-coloured urine, suggesting renal elimination of the absorbed test item. the study showed that mice were systematically exposed to hc yellow n° 7 until 24 or 8 hours post-dosing for males and females respectively. test substance was rapidly absorbed: plasma Cmax (23.1 and 27.5 µg/mL for males and females respectively) was reached after 0.25 h; however for males, a second Cmax (24.8 µg/mL) was noted at 1 hour post-gavage. total exposure was 95.72 µg/mL*h for males and 65.46 µg/mL*h for females; t1/2 was 7.85h for males and 5.54h for females. no major gender differences in the pharmacokinetic profile and parameters. this study showed good bioavailability of hc yellow n° 7 following oral administration to mice. ref.: 13 ";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
p-aminophenol;/;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_078.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"species/strain: rats, male, female, sprague-dawley, SPF-quality. test substance: 14C-labelled test substance incorporated in a hair dye formulation (A, D) and in an aqueous solution (B, C, E). batch: 2(WSI-111). purity: 99%. study groups: A: 0.5 h dermal exposure (formulation), sacrifice after 72 h B: 0.5 h dermal exposure (solution), sacrifice after 72 h C: 72 h oral exposure (solution) D: 0.5 h dermal exposure (formulation), sacrifice after 24 h E: 24 h oral exposure (solution). dose level: A 0.66 mg/cm² of the test substance (56.9 mg/cm² of formulation) B 0.56 mg/cm² of the test substance (33.6 mg/cm² of solution) D 0.65 mg/cm² of the test substance (56.6 mg/cm² of formulation) C 26.3 mg/kg bw E 26.9 mg/kg bw. exposure time: 30 min dermal exposure and 24 h or 72 h follow up. GLP: not in compliance. 5 male and 5 female sprague-dawley rats (Him: OFA, SPF) were used in each of the 5 experiments. the bodyweights were approximately 200 g. the 14C-labelled test substance was integrated in a hair dyeing formulation (0.18% 14C-""WSI-111"", 0.98% ""WSI-111"", 1% p-Phenylenediamine hydrochloride, 97.94% basic formulation) or used as a solution in water (B: 16.7 mg/ml, C and E: 5 mg/ml). the stability of the test substance (in solution and in formulation) was checked and considered satisfactory. the hair dyeing formulation was mixed with oxigenta lotion (containing 6% hydrogen peroxide) before application. the test substance was applied to the clipped dorsal skin of rats (3 cm x 3 cm) for 30 min and then washed off. the concentration on skin was 0.58% (formulation) and 0.5% (solution). radioactivity of rinsings, application site, urine, faeces, blood, organs and carcass was estimated by liquid scintillation counting. groups C and E received the test solution (about 26 mg/kg bw) orally by stomach tube. group C was sacrificed after 72 h and urine, faeces, organs, and carcass without gastrointestinal tract were examined for radioactivity. group E was killed after 24 h and radioactivity was determined in the blood. results dermal application: under the experimental conditions, total recoveries of the test substance of 97.7% (formulation) and 99.3% (aqueous solution) were obtained. the majority of the applied 14Clabelled test substance was removed from the skin with the washing procedure (95.5% for the formulation and 96.1% for the aqueous solution). the amount of 14C penetrated was calculated by adding the amounts eliminated from the body (i.e. urine 0-72 h plus faeces 0- 72 h) and the amounts of 14C still being present in the carcass. when the formulation was used (group A), the application site contained a mean 14Cactivity of 2.1% of the dosed 14C and 3% when the test substance solution was applied. in the animals of group D, the blood level of radioactivity was highest at 35 min p.a. and declined with a half-life of approximately 50 min. in groups A and B, the observed detection limit ranged from ca. 0.0005% dose/g for thyroids to 0.00002% dose/g for large organs (i.e., ca. 0.03-0.001 μg equivalents of the test substance/g). mean radioactivity concentrations in blood and the 14 analysed organs were all below or at the detection limit in groups A and B at 72 h after dosing. the radioactivity was excreted mainly via urine (82 - 89% of eliminated 14C) and to a lesser extent via faeces (11 - 18% of eliminated 14C). the excretion was fast: A mean of 99% of the totally eliminated 14C was excreted within the first 24 h in groups A and B. relatively highest concentrations of radioactivity were determined in group A in thyroids, adrenals and femur and in group B in thyroids, carcass and skin. the mean percutaneous penetration of the test substance was 0.078% of the administered 14C for the formulation (0.515 μg/cm²) and 0.128% (0.838 μg/cm²) for the aqueous solution. results oral dosing: after application of 26.3 mg test substance/kg bw, 83.7% were recovered in urine and 0.068% in the carcass at 72 h p.a. (group C). the radioactivity was excreted mainly via urine (88% of eliminated 14C) and to a lesser extent via faeces (12% of eliminated 14C). the excretion was fast: 99% of the total eliminated radioactivity was excreted within the first 24 h. in group C, the detection limit ranged from approximately 0.002% dose/g for thyroids to 0.00006% dose/g for large organs (i.e., ca. 0.01 and 0.003 μg equivalents of test substance/g). as far as can be judged from the very low 14C concentrations, the distribution into the organs was not too different from that observed after dermal application. In the blood and in the 14 analysed organs, the 14C-concentrations were below or near the detection limit. at 72 h p.a., relatively highest concentrations of radioactivity were found in thyroids, skin and kidneys, lowest in testes, brain and muscle. in the animals of group E, the blood levels of radioactivity were highest at 35 min. p.a. and declined with an initial half-life of approximately 40 min. an oral absorption of at least 83.8% (i.e., 22 mg test substance/kg bw) was calculated. experiments carried out with radio-labelled test formulations in toxicokinetic investigations including cutaneous and oral (gavage) application showed a low dermal penetration rate – between 0.08 and 0.13% of the applied radioactivity – compared with an absorption rate of about 84% after oral application; in both cases, more than 99% of the radioactivity was excreted during the first 24 hours after application, about 88% via urine. ref.: 15 (submission I)";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
p-aminophenol;/;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_078.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;taken from SCCP/1172/08. in vitro. cells: human intestinal epithelial cell line TC-7. test substance: 2-amino-hydroxyethylamino-anisole sulfate. batch: 57. purity: 99.6 area% (HPLC, 254 nm). test concentration: 50 µM in HBSS buffer containing 1 % DMSO. incubation time: 60 min. ref. compounds: propranolol, ranitidine and vinblastine. number of runs: two independent experiments. GLP: not in compliance, but QAU checked. the bioavailability of 2-amino-hydroxyethylamino-anisole sulfate across the intestinal barrier was investigated in human intestinal epithelial (TC-7) cells. the permeability from the apical (A, pH 6.5) to the basolateral (B, pH 7.4) side was investigated at 37°C in 96-well transwell plates with shaking for a 60 min contact time. analysis of the donor (apical) and receiver (basolateral) samples was done by means of HLPC-MS/MS and the apparent permeability coefficient (Papp) was calculated for two independent experiments. 14C-mannitol (about 4µM) was used to demonstrate the integrity of the cell monolayer. only monolayers revealing a permeability of < 2.5 x 10-6 cm/sec were used. propranolol, ranitidine and vinblastine were analysed concurrently to demonstrate the validity of the test system. according to the laboratory’s classification system, a low permeability is considered for test items revealing a Papp < 2 x 10-6 cm/sec. a Papp of 2 - 20 x 10-6 cm/sec and a Papp ≥ 20 x 10- 6 cm/sec classify a substance to have a moderate and a high permeability, respectively. ranitidine, which has a 50 % absorption in humans, was used as low permeability reference compound, as recommended by FDA. propranolol (Papp = 25.9 x 10-6 cm/sec) is a high permeability reference compound with 90 % absorption in humans. propranolol and ranitidine (Papp = 0.2 x 10-6 cm/sec) were well within the acceptance range for compounds of 20 – 45 x 10-6 cm/sec and 0.2 – 2 x 10-6 cm/sec, respectively and demonstrated the validity of the assay. 2-amino-hydroxyethylamino-anisole sulfate showed a Papp of 73.3 x 10-6 cm/sec. this was classified as high permeability, indicating a nearly 100% absorption from the gastrointestinal tract. ref.: 34. the study was not performed under GLP conditions, but a statement of the quality assurance unit of the test facility is included. there is no official guideline for this assay. however, the study was performed according to ECVAM recommendations. the generated data is considered to provide an estimation of the bioavailability of 2-aminohydroxyethylamino-anisole sulfate after oral administration.;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
p-aminophenol;/;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_078.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
p-aminophenol;/;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_078.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"animals were euthanized 96hr after dose administration and several tissues and organs were collected and analysed. metabolite profile in pooled urine and faeces samples were determined. 1 ADME; absorption %: 100, excretion % urine/faeces: 82/11. 2 ADME; absorption %: 101, excretion % urine/faeces 83/11. 3 ADME; absorption %: 3, excretion % urine/faeces 2/1. 4 ADME; absorption %: 63, excretion % urine/faeces 57/4. the average total radioactivity in all dose groups was between 94 and 101% of the applied dose. the oral absorption of amino-5-ethylphenol hydrochloride is high and fast. the dermal absorption is strongly dependent on the vehicle, the concentration dose and the duration of exposure. dermal absorption was also fast with a Tmax of 0.5 hours. large inter-individual variations were observed. amino-5-ethylphenol hydrochloride is mainly excreted by urine whatever the route of exposure. no major accumulation of radioactivity was observed after 96 hours. blood concentrations in all groups were around 10 times higher than in plasma concentrations, indicating distribution of the test substance into the red blood cells. 3 potential metabolites were detected in plasma, among them 2 were identified and 7 metabolites were detected in urine. sulfation, glucuronidation and acetylation were the major metabolic pathways whereas cysteine and glucose conjugation, carboxylation and hydroxylation were of minor importance. ";;;;amino-5-ethylphenol hydrochloride administered orally was extensively absorbed, largely distributed and extensively metabolized and excreted in urine. no major qualitative differences in the metabolite profile between the oral and dermal routes of administration were observed. the NOAEL derived from the 90 days oral toxicity study can be used to calculate the MoS without any adjustment.;;;;;;radiolabelled 2-amino-5-ethylphenol hydrochloride: 99.3. non radiolabelled 2-amino-5-ethylphenol hydrochloride: 99.9;;radiolabelled 2-amino-5-ethylphenol hydrochloride: cfq14698 batch 1. non radiolabelled 2-amino-5-ethylphenol hydrochloride: rd-cru 079- 16/97-05.;test substance: 2-amino-5-ethylphenol hydrochloride;;rat/wistar;;;f;4;;single, 1 ADME 75 mg/kg bw, 2 ADME 370 mg/kg bw, 3 ADME 16 mg/kg bw, 4 ADME 80 mg/kg bw;;;;;;0-8, 8-24, 24-48, 48-72 and 72-96hr;urine and faeces ;;;;group 3 : water milli-Q and off-white cream (representative of human use conditions): lanette O 8.4%, dusoran MD 1%, sodium laurylethersulfate 12%,  benz 28%, EDTA 0.12%, sodium sulphite 0.48%, ascorbic acid 0.36%, water 71.98%, ammonia: 5.46%. group 4: dimethylsulfoxide (DMSO to increase dermal absorption). group 1: phosphate buffered Ssaline (PBS). group 2: water milli-Q ;september 2006 – october 2006 ;yes;;36;"route of exposure: 1 ADME iv, 2 ADME oral, 3 ADME dermal, 4 ADME dermal. 3 ADME: 20 mg/mL; 0.2 mg/cm² – 0.5h and 4 ADME: 80 mg/kg bw; 100 mg/mL; 1 mg/cm² – 24h";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
p-aminophenol;/;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_078.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;in vitro metabolism of methoxymethyl-ppd sulfate in cryopreserved human hepatocytes. guideline: /. test system: cryopreserved human hepatocytes. test design: one experiment with suspended and one with plated hepatocytes. test substance: 2-methoxy-methyl-ppd-sulfate 14C-2-(methoxymethyl)benzene-1,4-diamine. batch: radiolabelled: cfq40317,b1 non-radiolabelled: gst070-05/24-01. purity: 99.5%. test concentrations: 1.0 and 10 µg/ml (suspended hepatocytes) 1.08, 10.8 and 107.08 µg/ml (plated hepatocytes). incubation time: 180 min. glp statement: not in compliance. study period: /. in this study, 2-(methoxymethyl)benzene-1,4-diamine sulfate was incubated with human suspended or plated hepatocytes to assess the metabolism. two concentrations (1.0 and 10 µg/ml) were tested for suspended hepatocytes and 3 for plated hepatocytes (1.08, 10.8 and 107.8 µg/ml). in the suspended hepatocytes incubations, only a n-monoacetylated metabolite was observed. the amount of the metabolite was greater at the highest concentration but did not increase proportionally (0.16 µg/ml at the low dose and 0.49 µg/ml at the high dose). in the plated hepatocytes study, two metabolites were observed: n-mono-acetylated and a cysteine conjugate. the amount of the monoacetylated metabolite increase in the dose range of 1.08 to 10.8 µg/ml but decrease in the dose range of 10.8 to 107.8 µg/ml. the cysteine conjugate was only found at the highest test concentration. two additional products were observed: one conjugate of 2-(methoxymethyl)benzene-1,4- diamine sulfate with glucose and a cyclisation product (not confirmed). ref.: 59. the cryo-conservation might impair some metabolising enzymes.;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
p-aminophenol;/;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_078.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;in vitro skin metabolism of 2-methoxymethyl-p-phenylene diamine sulfate following 24 hours incubation with hacat cells. guideline: /. test system: hacat cells (human keratinocytes). test substance: 14c-2-(methoxymethyl)benzene-1,4-diamine. batch: /. purity: /. vehicle: stable cell number media (dmem with 5% foetal bovine serum and 1% pen-strep diluted 1:10 in hbss with 2.15 g glucose). dose levels: 0.625, 1.25, 2.5, 5 and 10 µg/ml. glp statement: not in compliance. study period: 2010 In this study, 2-(methoxymethyl)benzene-1,4-diamine sulfate was incubated with human keratinocytes to assess the metabolism. five concentrations (0.625, 1.25, 2.5, 5 and 10 µg/ml) were tested. 2-(methoxymethyl)benzene-1,4-diamine sulphate is acetylated at the non-hindered amine position to monoacetylated 2-(methoxymethyl)benzene-1,4-diamine sulphate. as a second transformation step, this metabolite likely undergoes o-demethylation under the conditions applied. two additional products were observed: one conjugate of 2-(methoxymethyl)benzene-1,4- diamine sulfate with glucose and a cyclisation product (not confirmed). ref.: 60;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
n-methyl-2-pyrrolidone (NMP);;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_050.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
n-methyl-2-pyrrolidone (NMP);;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_050.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
n-methyl-2-pyrrolidone (NMP);;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_050.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
hydroxyethyl-2-nitro-p-toluidine ;/;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_061.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
o-phenylphenol, sodium o-phenylphenate and potassium o-phenylphenate;/;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_177.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
o-phenylphenol, sodium o-phenylphenate and potassium o-phenylphenate;/;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_177.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
n,n’-bis-(2-hydroxyethyl)-2-nitro-p-phenylenediamine;/;https://ec.europa.eu/health/sites/health/files/scientific_committees/consumer_safety/docs/sccs_o_196.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
hydroxyethyl-p-phenylenediamine sulfate ;/;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_017.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
hydroxyethyl-p-phenylenediamine sulfate ;/;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_017.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
hydroxyethoxyphenyl butanone ;OECD 428;https://ec.europa.eu/health/sites/health/files/scientific_committees/consumer_safety/docs/sccs_o_225.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
hydroxyethoxyphenyl butanone ;/;https://ec.europa.eu/health/sites/health/files/scientific_committees/consumer_safety/docs/sccs_o_225.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
hc yellow n°9;/;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_026.pdf;the test item was rapidly absorbed from the gastrointestinal tract. in plasma, the highest concentration of radioactivity 2.016 ppm (µg red (mip 2985) equivalents/g) was found 0.5 h after dosing. after reaching the maximum, the concentration in plasma decreased rapidly with an initial half-life of 1.3 h (initial phase, 1-2 h). between 4 and 24 h after dosing, a second, slower depletion phase (2-24 h) was seen with a depletion half-life of 8 hours. by 24 hours, the plasma concentration had decreased to 0.117 ppm. the AUC was 14.12 µg h/g. in the femur, the highest concentration of radioactivity 4.23 ppm (µg red (mip 2985) equivalents/g) was found 1 h after dosing. by 24 h post-dosing the concentration in femur decreased to 0.228 ppm. the depletion kinetics in the femur was similar to that seen in the plasma, with an initial half-life of 1.3 h and a depletion half-life of 10 h. it was assumed that the bone marrow of the femur was the main site of radioactivity;;;;;;;;;;95.9% (containing 4% inorganic salts), 98.15% (radio-labelled);;21187fc3, 3501-069 (radio-labelled);test substance: vibracolor red (mip 2985), ;radiolabelled vibracolor® red (mip 2985) final specific radioactivity of 846 kBq/mg (22.86 µCi/mg), 2072 MBq/mmol, 56 mCi/mmol;;mouse/ hybrid, nmri, spf-quality;;;f;;15;;33 mg/kg bw;single dose;;oral, gavage;;;;blood and femurs;0.5, 1, 2, 4, and 24h;water (milliq);;2004;yes;4, submission 2;a target volume of 0.5 ml per 100 g body weight.  at intervals, three animals were killed by CO2. blood and femurs from these animals were taken. radioactivity was measured by liquid scintillation of plasma and both femurs of each animal. ;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
hc yellow n° 13;/;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_044.pdf;red (mip 2985) was rapidly and almost completely absorbed from the gastrointestinal tract. the apparent extent of absorption, based essentially on the amount renally excreted, was calculated to at least 62 % of the dose. there appeared to be some bilary recirculation. the maximum concentration (Cmax) in blood and plasma was reached within 1 hour after administration accounting to 3.933 ppm and 4.785 ppm red (mip 2985 equivalents), respectively. a second lower maximum in blood and plasma was observed 6 hours postdosing. after reaching the second maximum, blood and plasma showed a biphasic depletion half-life of 15 and 9 h for the initial phase and 206 and 40 h for the second slower phase, respectively. the oral dose was rapidly eliminated. within 24 hours, 74 % of the dose was totally excreted, (53 % in urine, 17 % in the faeces and 4 % collected in the cage wash). by 96 days post-dosing, 93 % of the dose was eliminated. only 0.5 % of the dose is still remaining in tissues and carcass. the highest residue levels in tissues and organs were observed 24 hours post-dosing in the kidney (5.3643 ppm) and liver (4.0287 ppm), with low levels in fat (0.3267 ppm). the depletion kinetics in tissues and organs was similar to that seen in blood and plasma. the initial half-life was calculated to be in the range of 11-17 hours followed by a second slower phase with half life of 29-56 hours. two major metabolites, 1,3-dimethyl-imidazole-2-amine (about 50 % of the dose) and 1,4- diacetoaminobenzene (about 20% of the dose) and 6 minor metabolites were seen in urine and faeces. unchanged red (mip 2985) (1.5 % of the dose) was found in the faeces. due to the structure of the identified metabolites, the metabolic pathway suggested that the 1,3- dimethyl-imidazole-2-amine was a cleavage product of red (mip 2985) and that the 1,4- diacetoaminobenzene was the di-acetylation product of red (mip 2985) after demethylation of the (4-dimethylamino)phenyl site and cleavage of the azo bond;;;;rapidly and almost completely absorbed after oral dosing. the systemically absorbed test substance was metabolized and eliminated with urine and faeces;;;;;;95.9%, 98.15% (radio-labelled);;21187fc3, 3501-069 (radio-labelled);;"[14C] labelled red (mip 2985) with a final specific radioactivity of 204 kBq/mg (5.5 µCi/mg). radiolabelled batch: 2072 MBq/mmol; 56 mCi/mmol";;rat/wistar hanbrl:wist (spf): outbred;;;f;;9;;50 mg/kg bw;single dose;;oral, gavage;;;;blood, urine, faeces and cagewash;"0.5, 1, 2 4, 6, 8h (blood); 24, 48 and 96h (terminal blood); 0-24, 24-48, 48–72, and 72-96 h (urine and faeces).";water;;2005;yes;5, submission 2;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
hc yellow n° 13;/;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_044.pdf;"after 30 min dermal exposure to [14C] red (mip 2985), only 1.29% of the applied dose was systemically absorbed; 93-94% of the dose could be dislodged from the application site. after the skin washing, 2% of the dose remained in/on the treated skin area. the remaining radioactivity in/on the application site was found in the stratum corneum. less than 0.01% of the dose was determined in the dermis and subcutis. the quantity of test substance in the stratum corneum was virtually constant throughout the 96 h study period, indicating low penetration into deeper skin layers. the systemically absorbed test substance was rapidly excreted with the urine (1.08 %) and the faeces (0.14%).";;;;dermal absorption was very low;;;7.7;;;95.9%, 98.15% (radio-labelled);;21187fc3, 3501-069 (radio-labelled);;"[14C] labelled red (mip 2985) with a final specific radioactivity of 241 kBq/mg (6.52 µCi/mg). radiolabelled batch: 2072 MBq/mmol; 56 mCi/mmol";;rat, wistar HanBrl:WIST (SPF): outbred;;;f;;8;;0.2 mg/cm²;30 minutes single exposure;;;dermal;;;tape stripped skin(stratum corneum), skin wash, urine, faeces;24 and 96h;water;;2005;yes;5, submission 2;exposure site was washed and tape stripped to remove the unabsorbed test material;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
hydroxypropyl bis(n-hydroxyethyl-p-phenylenediamine) HCl;/;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_011.pdf;no clinical signs were observed in the oral dose groups (groups 2, 3, 6 and 7) or in the intravenous dose groups (groups 1 and 5), except for blue/green discolouration of the faeces at day 2 and some blue discolouration of the tail in one animal. after dermal dosing (groups 4 and 8), chromodacryorrhoea from nose and eye was observed. this was not a consequence of grooming, as the animals had neck collars. absorption and excretion: after oral dosing, the mean cumulative recovery of 14CTetrabromophenol blue radioactivity in the urine after 96 h was 0.031 ± 0.004% (low dose) and 0.03 ± 0.001% (high dose) and in faeces was 107.1 ± 5.06% (low dose) and 119.5 ± 6.618% (high dose). mean residual radioactivity in the carcass, tissues and blood was 0.244 % (low dose) and 0.353% (high dose). less than 0.02% of the total radioactivity was recovered in the cage wash. the mean mass balance was 107.40 ± 5.03 % (low dose) and 119.9.± 6.63% (high dose). the percentage of oral absorption was calculated by comparison of the percentage of radioactivity recovered in urine after oral administration with the percentage of radioactivity recovered in urine after iv administration which yielded 29 and 30%. after intravenous administration, the mean percent recovery of radioactivity after 96 h was 0.102 ± 0.013% in urine and 112.76 ± 14.30% in faeces. mean residual radioactivity in the carcass and tissues was 5.89% of the dose. less than 0.05 % of the total radioactivity was recovered in the cage wash. the mean mass balance was 113.49 ± 14.32%. after dermal application, the mean cumulative recovery of radioactivity was 0.013 ± 0.007% of the dose for the urine and 0.838 ± 0.248% of the applied dose for the faeces. mean residual radioactivity in the carcass and tissues (without skin) was 0.314%. the recovery from the treated skin was 0.369 ± 0.151%. less than 0.05 % of the total radioactivity was recovered in the cage wash. the mean mass balance was 97.332 ± 2.521%. the chromatograms from the 3 treatments showed similar characteristics, although radioactivity in the dermal group was low and only a vague peak pattern observed. hence, the results are based on the average of all groups. it was reported that no radioactivity peaks were detected in the urine samples. with both lc methods, two clusters of peaks were observed. in the first cluster, a peak with a retention time similar to 14C-tetrabromophenol blue was detected, indicating unchanged compound in the faeces. the second cluster was thought to be metabolites. 14C-tetrabromophenol blue has at least 5 components that differ in the number of bromine atoms (6-8). each of these forms metabolites. the major metabolic reactions resulted in metabolites with longer retention times on the lc system and with m/z ratios 2 amu (atomic mass unit) higher than the corresponding 14C-tetrabromophenol blue components. mass spectroscopic data on these metabolites did not yield sufficient information for proposal of a chemical structure because elimination of *Br and HBr were the main fragmentation reactions. the most important route of excretion of tetrabromophenol blue and its metabolites was through the faeces, suggesting some biliary excretion. with oral dosing, 107-119% of the administered dose was recovered in the faeces. after dermal administration, excretion via faeces was low, (0.8%), reflecting the poor dermal absorption. excretion in urine was low, representing 0.03-0.1% of the dose after oral and iv administration and 0.01% after dermal application. excretion of tetrabromophenol blue and its metabolites was much slower after dermal application, which was probably a sign of the slow dermal absorption and consequent slow systemic availability. toxicokinetics: oral toxicokinetics, over the dose range investigated, was linear with Cmax values of 0.431 mg/kg bw (low dose) and 7.32 mg/kg bw (high dose). AUC0 - ∞values were 4.58 and 111.0 mgeqhr/kg for the low and high dose groups respectively. the dose-normalised AUC values were in the same order of magnitude, i.e. 0.450 and 1.070, respectively. apparent terminal half-lives of 14C-tetrabromophenol blue were also similar in both oral administered groups with 19 and 15 hours, respectively. after intravenous administration, half-life was 23.04 hours. no toxicokinetic evaluation could be performed for the dermal group. ;;"oral: 20% (100mg/kg) and 30% (10mg/kg); dermal: 1.2%";"in faeces after oral administration: 107-119%; dermal administration: 0.8%. in urine after oral and iv: 0.03-0.1%";absorption, distribution, metabolism and excretion have been investigated in the female wistar rat. after oral administration, 14C-tetrabromophenol blue was moderately absorbed, readily distributed into all organs and excreted mainly via the faeces. the oral absorption of 14Ctetrabromophenol blue was moderate, 29% (100 mg/kg) and 30% (10 mg/kg). dermal absorption of 0.9% of aqueous 14C-tetrabromophenol blue was 1.2% of the applied dose. when dermally absorbed, excretion took place mainly via the faeces and the rate of elimination was slower than after oral dosing.;;;;;;radiochemical purity: 88.8% by hplc, specific activity 48.8 mCi/mmol non-labelled: 97.5% (HPLC, 254 nm) ;;064k9418 (labelled), tbfb3/02/30 (not labelled);test substance: tetrabromophenol blue (non-labelled);tetrabromophenol blue-(phenol-UL-14C);;rat/ wistar CRL: WI BR (outbreed) (SPF);;;f;;"mass balance groups (groups 1,2,3,4) 4 per dose; toxicokinetics groups (groups 5, 6, 7, 8) 6 per dose ";;oral: 10 and 100 mg/kg bw by gavage, intravenous: 5 ml/kg, dermal: 9 mg/kg bw (equivalent to 0.09 mg/cm² skin, 9 mg/ml). ;single;;;;;;urine, faeces, tissues, organs and blood;in the mass-balance groups, after dosing, urine and faeces were collected over time intervals of 0-8 h, 8-24 h, 24-48 h, 48-72 h, 72-96 h. the animals were killed after 96 h and several tissues and organs were collected. total radioactivity in urine, faeces, tissues, and organs was determined. for metabolic studies, urine and faeces were pooled per group, and the metabolite profile of the pooled samples was obtained by hplc and lc-ms/ms. in the toxicokinetic groups, blood was sampled alternately from several rats per time point at 15 and 30 min, and 1, 2, 4, 8, 24, and 48 h. total radioactivity tetrabromophenol blue equivalent concentrations were determined.;oral: 5.3% w/w polyglycol 600, 4.2% w/w Plantaren 2000 UP (50% aqueous decyl glucoside), 90.5% milli-U water, intravenous: 0.05 M phosphate buffer (pH 7.6), dermal: water/acetone 1:1 ;in the dermal part of the study, a 0.9% solution was applied while only 0.2% was requested by the applicant. chromodacryorrhoea from the nose and eye were observed. chromodacryorrhoea was seen in females in the 90-day study at the 10 mg/kg bw/d and 100 mg/kg bw/d doses. ;2005;yes;10 (submission 2) ;"homogeneity and stability of test substance in the vehicle were demonstrated by hplc. accuracy of concentrations was sufficient to fulfil the study objectives. one animal (group 2; low oral dose group) died on day 2, probably due to misdosing. ";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
hydroxypropyl bis(n-hydroxyethyl-p-phenylenediamine) HCl;/;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_011.pdf;all animals appeared healthy and no overt signs of toxicity were observed throughout the study. at approximately 0.5 hours post-dose, all animals in the dermal groups (groups 3, 4, 7 and 8) had an orange-coloured dose site. at approximately 24 hours post-dose, all animals (in groups 4 and 8) had a red-coloured dose site.;;;;14C-1-hexyl-1H-pyrazole-4,5-diamine hemisulfate administered orally was extensively absorbed (at least 82%), readily distributed, extensively metabolised, and excreted mainly in the urine. dermal absorption of 14C-1-hexyl-1H-pyrazole-4,5-diamine hemisulfate was relatively slower and lower (8.79%) after a 30-min exposure period and moderate (16.8%) after a 24-hour exposure period. when absorbed, radioactivity was excreted almost similarly in both urine and faeces. 14C-1-Hexyl-1H-pyrazole-4,5-diamine hemisulfate was extensively metabolised via both Phase I and Phase II biotransformation pathways after all dosing routes. the major biotransformation pathway was N-acetylation mainly in combination with oxidation and with glucuronidation.;;;;;;99.1, 98.4 (radio-labelled);;"RD-CRU-096-07/142-01; cfq1662 (radio-labelled)";test substance: 1-hexyl-1H-pyrazole-4,5-diamine hemisulfate and 14C-1-hexyl-1H-pyrazole-4,5-diamine hemisulfate;14C, labelled on the carbon in the 5th position, specific activity: 25 mCi/mmol ;;rat/sprague dawley, (hsd:spraque dawley sd);;;f;;6 (mass balance groups (groups 1, 2, 3, 4)), 4 (iv and oral toxicokinetic groups (groups 5 and 6)), 8 (dermal toxicokinetic groups (groups 7 and 8));;"intravenous administration: 11.9 mg/kg bw (containing approximately 19.7 µCi/mg of radioactivity); oral administration: 12 mg/kg bw (containing approximately 19.5 µCi/mg of radioactivity); dermal administration: 11.0 mg/kg bw (groups 3 and 7) and 11.5 mg/kg bw (groups 4 and 8) – equal to 0.186 mg/cm² and 0.208 mg/cm², respectively (containing approximately 83.0 / 83.1 µCi/mg of radioactivity, respectively)";single dose;yes;yes, gavage;yes;;;blood, plasma, urine, faeces (after combustion), cage rinse, cage wash, and dermal apparatus/skin washes/rinse sample;"mass balance groups: groups 1 and 2: 0.25, 0.5, 1, 2, 8, 24, 48, 72, 96, 120, 144 and 168 hours post-dose; groups 3 and 4: 0.5 (prior to skin wash, if applicable), 1, 2, 4, 8, 24 (prior to skin wash, if applicable), 48, 72, 96, 120, 144 and 168 hours post-dose. toxicokinetic groups (groups 5, 6, 7, 8): urine was collected at 0-8 and 8-24 hours post-dose, and at 24-hour internals through 168 post-dose. faeces were collected at 24-hour internals through 168 post-dose. after each24-hour excreta collection through 144 hours post-dose, cages were rinsed with water and the samples were collected. After the last excreta collections, cages were washed and wipedand cage wash samples and gauze pads were collected; dermal groups (groups 3, 4, 7 and 8): 0.5 or 24 hours post-dose; metabolite profiling and identification: from 0.25 hour (0.5 hour for dermal groups) to 144 hours (168 hours for dermal groups) post-dose. ";"intravenous administration: 0.1% ascorbic acid in aqueous sodium hydroxide (pH 6.81); oral administration: 0.1% ascorbic acid in aqueous sodium hydroxide (pH 6.06); dermal administration (0.5 hour): 0.1% ascorbic acid in aqueous sodium hydroxide; dermal administration (24 hours): 10% (w/v) propylene glycol and 0.1% (w/v) ascorbic acid in aqueous sodium hydroxide (pH 6.90)";"no justification for the use of ascorbic acid (0.1%) in the test vehicles for iv, oral and dermal administration was given. no justification for the addition of 10% (w/v) propylene glycol in the test vehicle for the 24-hour dermal administration was given. the sccs noted the relatively low total recovery of radioactivity in the dermal groups of 71.6% (dermal 0.5 hour exposure) and 73.1% (dermal 24 hours exposure) which,according to the study report authors, was likely caused by insufficient skin and cage wash.
according to the applicant, this is considered to be of no relevance for systemic availability following dermal exposure. the calculated systemically available dose for 1% 1-hexyl 4,5-diamine pyrazole sulfate of 3.78 μg/cm² (mean + 1 SD) from the dermal in vitro study will be used for the MoS calculation. 14C-1-Hexyl 4,5-diamine pyrazole sulfate administered orally was extensively absorbed (> 82%). an oral absorption of 82% is used for the MOS calculation. ";2013;yes;34;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
basic red 51;OECD 417;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_067.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
basic red 51;OECD 417;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_067.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
basic red 51;OECD 417;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_067.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
tetrabromophenol blue;OECD 417 + 427;https://ec.europa.eu/health/sites/health/files/scientific_committees/consumer_safety/docs/sccs_o_232.pdf;"this study was conducted immediately after the in vitro percutaneous penetration study and used the same test item and dosing mixtures. the nominal dose was 100 mg test item per kg body weight. all 4 animals survived the study period, gained weight, and did not show signs of toxicity or adverse effects. administered doses ranged from 113 to 117 mg eth50 /kg bw with mean of 115.5 mg/kg bw and 912.98 kBq/animal. absorption into systemic circulation based on urinary excretion was 0.06% of applied dose. the maximum concentration level in blood was achieved 1 hour after administration, accounting for 0.360 µg fat 65080 equivalents/g. this concentration level remained almost constant until 8 hours post dosing. thereafter the concentration decreased with a terminal half-life of about 31 hours. the AUC values, being an index of bioavailability, were calculated to be 17.9 µg·h/g for blood. blood and plasma did not show differences in distribution of the test item. radiolabelled test item did not exceed LOQ in any tissue or organ at 96-hours after dosing; the LOQ was about 0.091 µg-equivalents per gram except for fat, which was 0.182 µg-equivalents/g. only the remaining carcass (LOQ of 0.012 µg-equivalents/g) showed measurable quantities of test item that approximated 0.07 (+ 0.01)% of the applied dose. elimination was almost fully via faeces and accounted for 93.34% of administered dose or 99.8% of the recovered excreted radioactive material. urine, representing absorbed radioactive material, was 0.06% of the total amount administered. total recovery was 93.56% of administered radioactivity during the study period. ";;0.06%;93.49% of administered dose or 99.8% of the recovered excreted radioactive material.;the study authors concluded that there was only minimal absorption for the nano sized (d(0.5) = 86 nm) eth50 from the gastro-intestinal tract.;;;;;0.8 mL of the test substance was diluted in 2.4 mL purified water to prepare the oral gavage mixture dosed at 1.0 mL per animal.;non-radiolabelled: 98% ;;non-radiolabelled: koc00050/004e;test substance: non-radiolabelled fat 65’080 . particle size: d(0.5)= 86 nm (mean of 2 measurements) ;radiolabelled batch: 49336-1-61. purity : >99%. test substance:  [14C]-labelled fat 65’080, nanosized with surfactant (plantacare®2000 UP), thickener (xanthan gum) and emulsifier (propylene glycol) to mixture of 90.88 mg [14C]-labelled fat 65’080/ml. specific activity of the mixture: 1.07 µCi/mg;;rat/ hanrcc:wist (spf): wistar ;;;m;;4;;100 mg/kg bw ;;;yes, gavage;;;;"urine and faeces samples for each of four 24-hour periods were collected individually and separately per metabolism cage; urine was collected into containers on dry ice, faeces at room temperature and the daily collections stored frozen until analysis. study termination at 96-hours after dosing was by CO2 anaesthesia and exsanguinations, during which blood was collected from each animal. cages were rinsed separately. samples of liver, kidney, renal fat, muscle were taken, and as the remaining carcass, analysed for radioactivity. ";;;although not specifically required by oecd 417, it would have been informative to analyse other major organs like spleen, lung and brain for radio-activity. the applicant assumed that the absorption was mainly due to impurities present in the radio-labelled product. although co-labelling of impurities indeed cannot be excluded, no reason was presented by the applicant why impurities should have a preferred higher absorption than eth-50 itself. therefore it is assumed that the measured radioactivity is derived from the absorbed radiolabelled active ingredient. for comparison between the toxicokinetic behaviour of the particles in nano- and non-nano size, also a ADME study in male rats with particles with a mean size of 6 µm has been carried out.;;yes;3 (subm 3);in vivo oral absorption, distribution, and elimination- rat. nano-sized material. dose in mg a.i./kg bw 113 : total particles dosed (number) 5.22E+13: number of particles/kg bw 2.61E+14 : surface area of particles dosed (m2) 1.24/  dose in mg a.i./kg bw 117 : total particles dosed (number) 5.40E+13: number of particles/kg bw 2.70E+14 : surface area of particles dosed (m2) 1.28. the nominal dose was 100 mg test item per kg body weight.;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
1-hexyl 4,5-diamino pyrazole sulfate;OECD 417 and 427;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_181.pdf;[14C] fat 65080 (d(0.5) = 6 µm) was administered to male rats at a nominal dose level of 100 mg/kg bw. the blood and plasma kinetics after oral administration was investigated. additionally the urinary and faecal metabolite pattern was established. after oral administration the test item was very poorly absorbed from the gastro intestinal tract into system circulation. the extent of absorption, calculated based on the urinary excretion, accounted for 0.73% of the administered dose. almost the complete dose was excreted unabsorbed with the faeces as unchanged parent compound, accounting for 97.2 % of dose within 48 hours after administration. the maximum concentration of radioactivity in blood and plasma was achieved 1 hour after administration, accounting for 2.463 and 4.359 μg fat65080 equivalents/g, respectively. this plateau level remained constant until 8 hours post dosing. thereafter the concentrations in blood and plasma decreased with a half-life (8-48 h) of about 13 hours. the AUC values (0-96 h) were calculated to be 65.2 and 114.3 μg·h/g for blood and plasma, respectively. the tissue residues, 96 hours after administration, were consequently very low. the highest concentration was found in abdominal fat accounting for 1.712 μg fat 65080 equivalents/g. all other selected tissues and organs revealed concentrations below 0.110 μg fat65080 equivalents/g. the urinary metabolite pattern investigated revealed 7 metabolite fractions. however, the major fraction (U7) represented only 0.19 % of the dose. all other fractions were below 0.1 % of the dose. the faecal metabolite pattern consisted essentially of unchanged fat 65080.;;0.73%;97.2%;in summary, after oral administration of [14C] fat65080 only a very low amount of radioactivity was absorbed from the gastrointestinal tract and almost the complete dose was excreted unabsorbed as unchanged parent with the faeces.;;;;the final micro suspension had a concentration of 17.4 mg/test item/ml suspension.;;non-radiolabelled: 98%;;non-radiolabelled: KOC00050/004E;test substance: fat 65’080,particle size: d0.5 =6 µm;"test substance :[14C] labelled fat 65’080; micronised and filled up with CMC solution (= 0.5% carboxymethylcellulose and 0.4% Tween 80). batch  radiolabelled: 49336-1-61. purity radiolabeled: >99%.";;rat/ hanrcc:wist (spf): wistar;;;m;;2 groups, group 1 mass balance: 4 rats, group 2 blood kinetics: 9 rats;;100 mg/kg bw;;;yes, gavage;;;;urine and faeces /  blood, plasma, liver, kidneys, muscle, and fat  ;daily intervals up to 96h / 96h after administration;;;;yes;4 (subm 3);in vivo oral absorption, distribution, and elimination- rat. non-nano size. ;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
1-hexyl 4,5-diamino pyrazole sulfate;/;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_181.pdf;14C-1-hydroxyethyl-4,5-diamino pyrazole sulfate was readily absorbed and rapidly excreted after oral administration in wistar kyoto rats. mean cumulative recovery of radioactivity: in the urine after 96 h was 73.3 + 8.3% (low dose) and 75.7 + 2.5% (high dose) of the applied dose, in faeces was 28.3 + 2.3% (lowdose) and 22.9 + 1.0% (high dose) of the applied dose, in the carcass, tissues and blood was 0.9% (low dose) and 0.6% (high dose) of the applied dose. less than 5% of the total radioactivity was recovered in the cage wash. the mean mass balance was 107.1 + 8.8% (low dose) and 101.3 + 2.4% (high dose). the mean percent recovery of radioactivity after intravenous administration after 96 h was 86.9 + 8.0% in urine and 6.0 + 2.6% in faeces. mean residual radioactivity in the carcass, tissues, and blood was 0.9% of the applied dose. less than 3% of the total radioactivity was recovered in the cage wash. the mean mass balance was 96.7 + 4.6%. after dermal application, the mean cumulative recovery of radioactivity was 0.8 + 0.5% of the applied dose for the urine and 0.8 + 0.5% of the applied dose for the faeces. mean residual radioactivity in the carcass, tissues and blood was 2.4%, and the majority of this was recovered from treated skin (1.7 + 0.8%). less than 0.1% of the total radioactivity was recovered in the cage wash. the mean mass balance was 91.1 + 3.3%. in the urine, five different metabolites could be distinguished after oral 14C-1-hydroxyethyl4,5-diamino pyrazole sulfate administration. in the high oral dose group, the parent compound could be detected. the majority of the radioactivity present in urine, about 90%, could be assigned to three major metabolites. in the faeces, five different metabolites could also be distinguished. the majority of the radioactivity present in faeces, about 90%, could be assigned to two major metabolites. the urine and faeces samples appear to have one major metabolite in common. detection of unabsorbed 14C-1-hydroxyethyl-4,5-diamino pyrazole sulfate in faeces remained questionable due to inconsistent analytical results. radioactivity in urine after dermal application was too low for an accurate detection of metabolites. however, lc-ms/ms analysis suggested a quantitatively similar profile of metabolites as the one seen after oral administration. after i.v. dosing inconsistent analytical results were obtained. characterisation of metabolites was difficult, since no standards were available. however, three metabolites were characterised (by pda and ms detector). It appears that 14C-1- hydroxyethyl-4,5-diamino pyrazole sulfate is metabolised through oxidative reactions and n-acetyl conjugation. two metabolites appeared to be present as dimers probably due to chemical conversion after sampling but in vivo formation cannot be excluded. the most important route of excretion of 14C-1-hydroxyethyl-4,5-diamino pyrazole sulfate and its metabolites was via urine after oral and i.v. administration. in both oral dose groups, 63-78% of the administered dose was recovered in the urine, showing that no metabolic saturation occurred at the high dose level. urinary excretion after dermal administration was low, (0.8%), reflecting the poor dermal absorption. the terminal rate of excretion was much slower than in the other groups. excretion in faeces was a far less important route of excretion, representing 3-30% of the dose after oral and i.v. administration, and 0.8% after dermal application. the amount of radioactivity excreted in the faeces was higher after oral dosing compared to intravenous dosing, indicating that the majority of the radioactivity in the faeces after oral dosing may represent 14C-1-hydroxyethyl-4,5-diamino pyrazole sulfate. after oral, iv and dermal dosing radioactivity in organs was very low. the highest residues were found in the carcass (0.4-0.8%). after dermal dosing radioactivity recovered from treated skin was 1.7%. toxicokinetic results indicate that a good dose proportionality was achieved with Cmax values of 5.50 mg/kg bw (low dose) and 170.81 mg/kg bw (high dose). the rate of oral absorption of 14C-1-hydroxyethyl-4,5-diamino pyrazole sulfate was fast, with maximum plasma concentrations reached one hour after administration in both groups indicating no saturation of absorption at the high dose level. AUC0→∞ values were 24.10 and 600.46 mgeqhr/kg bw for the low and high dose groups, respectively. the dose-normalised AUC values were quite similar, i.e. 2.23 and 2.38, respectively. the rate of absorption after dermal administration was faster than after oral administration, since the maximum plasma concentrations were reached 30 min after dosing. however, plasma concentration values remained low, leading to relatively low AUC values (AUC0→∞ = 0.36 mgeqh/kg bw and 0.02 for the respective dose-normalized value, both calculated as approximations since at some time points the plasma concentrations were below the limit of quantification). in plasma samples of the high oral dose group taken within 2h after dosing, 14C-1- hydroxyethyl-4,5-diamino pyrazole sulfate could be detected. the concentrations rapidly decreased with time. therefore, 1-hydroxyethyl-4,5-diamino pyrazole sulfate appears to be quickly metabolised. no 14C-1-hydroxyethyl-4,5-diamino pyrazole sulfate was detected in any of the samples from the other groups. one metabolite peak was present in the plasma samples following oral and i.v. administration. after dermal application nothing was detected at any time point due to low radioactivity levels. ;;;;absorption, distribution, metabolism and excretion have been investigated in the female wistar kyoto rat, a strain with a low acetylator phenotype. after oral administration, test item was extensively absorbed, readily distributed into all organs, extensively metabolised and excreted via the urine and faeces. oral absorption  was high, between 78-83%. dermal absorption was low: 2.4% of the applied dose or 0.006 mg/cm2 . since it cannot be excluded that the amount retained in the application site skin may eventually become systemically available, the skin residue dose was considered potentially absorbed and potentially systemically available. thus, as a worst case assumption, dermal bioavailability was calculated as 4% of the applied dose, or 0.01 mg/cm2. when dermally absorbed, excretion took place mainly via the faeces and the rate of elimination was slower than after oral administration. analytical results indicate extensive metabolism after both oral and dermal administration. efforts to characterise the urinary metabolites indicate the presence of oxidative and n-acetylated metabolites.;;homogeneity and stability of test substance formulations in the vehicle were demonstrated by hplc. accuracy of concentrations was sufficient to fulfil the study objectives.;;;;99.6 (non-labelled, 254 nm);;r0070335 (robinson 7326hlo73) ;test substance: wr 18247;"[ring-14C(U)]-1-hydroxyethyl-4,5-diamino pyrazole sulfate, batch :01bly099; radiochemical purity: >98% by hplc, specific activity 15 mCi/mmol ";;rat/wistar kyoto, wky/nr crl br (inbred);;;f;;"4 in the mass balance groups (four groups) per dose; 6 in the toxicokinetics groups (four groups) per dose";;"intravenous administration: 10 mg/kg bw; oral administration: 10, 250 mg/kg bw; dermal administration: 20 mg/kg bw (equal to 0.3 mg/cm² skin and 30 mg/ml or 3%)";single ;intravenous;oral, gavage;dermal with 30minutes exposure on the back ;;;urine, faeces, blood;"urine and faeces collected at 0-8 h, 8-24 h, 24-48 h, 48-72 h, 72-96 h (oral and i.v. administration groups). animals euthanised at 96 h after dose administration.in the dermally dosed group urine and faeces were collected at a 24 h interval and animals were sacrificed at 120 h. in the toxicokinetic groups: 15 and 30 min and 1, 2, 4, 8, 24, and 48 h after dosing (oral and i.v. groups); 30 min and 1, 2, 4, 8, 24, 48 and 72 h after dosing (dermal group).";"milli-q (oral and dermal dosing) and 0.9% saline (intravenous dosing); solutions contained 0.3% sodium sulphite and were adjusted to pH 7-8 with ammonia 25%";;;yes;26;ror metabolism evaluation, urine and faeces samples were pooled per group, and the metabolite profile of the pooled samples was obtained by hplc and lc-ms/ms.;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
1-hexyl 4,5-diamino pyrazole sulfate;/;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_181.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
1-hexyl 4,5-diamino pyrazole sulfate;/;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_181.pdf;the average total recovery of radioactivity in the mass balance groups (1-4) was between 97 and 99 % of the applied dose. overall absorption after oral administration was very high (> 95 % of the administered dose). after dermal application, a significantly lower absorption rate (5 % equal to 8 µg/cm²) was obtained based on the content in the carcass, urine and faeces. when also taking the amount present at the application site into account, the potentially absorbed fraction was 8% of the applied dose, or 148µg/cm². blood kinetics revealed a very fast absorption after oral administration for both the low and the high dose. after oral application of the test substance, the highest concentration of the test compound in the blood samples was observed after 10 min, the first time point of sampling. the absorption after dermal application was slower, but still relatively fast, as the maximum blood levels were noted after 1 h. the most important route of excretion of 14C- hydroxyethyl-3,4-methylenedioxyaniline HCl and its metabolites for all routes of administration was the urine. excretion via faeces was significantly less important in all groups. since the observed proportion of the radioactivity excreted through the faeces was similar after i. v. and after oral application, the amount found in the faeces after oral application is considered to represent phase II metabolites of the dye that have been excreted via the bile. the metabolite profile in the urine samples and faeces extracts was similar between the different dosing routes. only metabolised hydroxyethyl-3,4-methylenedioxyaniline HCl was detected in urine and faeces, thus demonstrating that the test substance is rapidly and extensively metabolised in the Wistar Kyoto rat. no conjugates were found in urine or faeces, suggesting that the metabolite itself is excreted in bile or a glucuronide conjugate is formed and excreted via bile, and is de-conjugated in the intestines. at termination of the study, the highest residual levels of radioactivity were found in the carcass, liver, kidney and thyroid, but were very low (about 1% of the applied dose for oral and i.v. application). in the dermal group, about 5% of the applied dose was recovered in the carcass, with the majority found in the skin from the application site. the investigated organs contained no or only a very low level of radioactivity. the described low residual levels in the animals after termination of the study do not indicate bioaccumulation of hydroxyethyl-3,4-methylenedioxyaniline HCl.;;;;after oral administration, rapidly and efficiently absorbed, readily distributed in the organism, extensively metabolised and quickly and almost quantitatively excreted, mainly via urine. after dermal application the absorbed amount was very limited. once absorbed, the routes and rates of elimination were similar for all three routes of administration (i.v., oral and dermal). no differences in the metabolite profile between the routes of administration or between gender were observed and no tendency for bioaccumulation was noted in this study;;;7.0 – 8.5;;;99.7, 100 (radio-labelled);;"9/93 Fass 195; 01BLY060 (radio-labelled)";test substance I: 14C-hydroxyethyl-3,4-methylenedioxyaniline HCl, test substance II: hydroxyethyl-3,4-methylenedioxyaniline HCl ;14C-hydroxyethyl-3,4-methylenedioxyaniline HCl (ring-labelled, specific activity 60 mCi/mmol);;rat/ wistar kyoto wky/nr crl br (inbred);;;f;the rats were fasted for approximately 18 h prior to and 4 h after dose administration (oral administration). animals used for intravenous dosing were not fasted.;"4 (group 1-4, mass balance study); toxicokinetics: 8 (group 5), 6 (group 6+7), 5 (group 8)";;"group 1 + 5: 1 mg/kg bw; group 2 + 6: 1 mg/kg bw (low oral dose); groups 3 + 7: 100 mg/kg bw (high oral dose); group 4 + 8: 1.5 % (equivalent to 10 mg/kg bw and 0.15 mg/cm2) ";single application;yes, tail-vain;oral, gavage;dermal, shaved back skin;;;urine, faeces, blood, tissues and numerous organs;groups 1-4: 0-8, 8-24, 24- 48, 48-72 and 72-96 h after administration. in the toxicokinetic groups: 10, 20, 40 min and at 1, 2, 4, 8, 24 and 48 hours (group 8: additionally at 72 hours) after dosing.;"group 1 + 5: sterile physiological saline solution (0.9 %) for intravenous administration; pH adjusted to 7.0 – 8.5;  group 2, 3, 6 + 7: water; group 4 + 8: acetone/water 1:1 for dermal application; pH adjusted to 7.0 – 8.5";;;yes;33;oral administration : volume of 5 ml/kg bw. intravenous administration:  volume of 2 ml/kg bw. dermal application: the intention in this part of the study was not to simulate realistic exposure scenarios, but to obtain high penetration rates to compare metabolite profiles. therefore acetone/water was used as vehicle. approximately 24 h prior to treatment, a 5 x 6 cm area of the fur on the back of the animals and a 4 x 4 cm area of the fur in the abdominal region was shaved. on the shaved skin on the back an area of 2.5 x 4 cm was marked as application site. shaved area in the abdominal region served as negative control. immediately prior to treatment, the application site was cleaned with a 10 % shampoo solution and water, and then dried. application, exposure and removal were done under anaesthesia. after the treatment period of 30 minutes, the application site was rinsed with an aqueous shampoo formulation. during the entire study period, animals wore plastic collars to avoid licking of the treated area.;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
1,3,5-triazine, 2,4,6-tris(1,1'-biphenyl)-4-yl-;OECD 417;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_070.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
1,3,5-triazine, 2,4,6-tris(1,1'-biphenyl)-4-yl-;OECD 417;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_070.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
1-hydroxyethyl-4,5-diamino pyrazole sulfate;OECD 417 + OECD 427;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_079.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
hydroxyethyl-3,4-methylenedioxyaniline HCl;/;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_006.pdf;"blood were sampled after dosing and equivalent concentrations of amino-5-ethylphenol hydrochloride were determined. 5 TK; F abs %: na, Cmax mg/kg: na, AUC last: 270. 6 TK; F abs %: 60, Cmax mg/kg: 96.8, AUC last: 828. 7 TK; F abs %: 2, Cmax mg/kg: 1.04, AUC last: 1.04. 8 TK; F abs %: 56, Cmax mg/kg :39.8, AUC last: 173. the average total radioactivity in all dose groups was between 94 and 101% of the applied dose. the oral absorption of amino-5-ethylphenol hydrochloride is high and fast. the dermal absorption is strongly dependent on the vehicle, the concentration dose and the duration of exposure. dermal absorption was also fast with a Tmax of 0.5 hours. large inter-individual variations were observed. amino-5-ethylphenol hydrochloride is mainly excreted by urine whatever the route of exposure. no major accumulation of radioactivity was observed after 96 hours. blood concentrations in all groups were around 10 times higher than in plasma concentrations, indicating distribution of the test substance into the red blood cells. 3 potential metabolites were detected in plasma, among them 2 were identified and 7 metabolites were detected in urine. sulfation, glucuronidation and acetylation were the major metabolic pathways whereas cysteine and glucose conjugation, carboxylation and hydroxylation were of minor importance. ";;;;amino-5-ethylphenol hydrochloride administered orally was extensively absorbed, largely distributed and extensively metabolized and excreted in urine. no major qualitative differences in the metabolite profile between the oral and dermal routes of administration were observed. the NOAEL derived from the 90 days oral toxicity study can be used to calculate the MoS without any adjustment.;;;;;;radiolabelled 2-amino-5-ethylphenol hydrochloride: 99.3. non radiolabelled 2-amino-5-ethylphenol hydrochloride: 99.9;;radiolabelled 2-amino-5-ethylphenol hydrochloride: cfq14698 batch 1. non radiolabelled 2-amino-5-ethylphenol hydrochloride: rd-cru 079- 16/97-05.;test substance: 2-amino-5-ethylphenol hydrochloride;;;rat/wistar;;;f;;6;;(5 TK) 75 mg/kg bw , (6 TK) 370 mg/kg bw, (7 TK) 16 mg/kg bw , (8 TK) 80 mg/kg bw;single;5 TK;6 TK;7 TK, 8 TK;;;blood;0.25, 0.5, 1, 2, 4, 8, 24, 48 and 72h ;group 7 : water milli-Q and off-white cream (representative of human use conditions): lanette O 8.4%, dusoran MD 1%, sodium laurylethersulfate 12%,  benz 28%, EDTA 0.12%, sodium sulphite 0.48%, ascorbic acid 0.36%, water 71.98%, ammonia: 5.46%. group 8: dimethylsulfoxide (DMSO to increase dermal absorption). group 5: phosphate buffered Ssaline (PBS). group 6: water milli-Q.;;2006;yes;36;"7 TK: 20 mg/mL; 0.2 mg/cm²– 0.5h and 8 TK: 100 mg/mL; 1 mg/cm²– 24h";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
hydroxyethyl-3,4-methylenedioxyaniline HCl;OECD 417 + 427;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_006.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
hc yellow n° 7;/;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_032.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
2,6-dihydroxyethylaminotoluene;/;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_188.pdf    ;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
2-amino-4-hydroxyethylaminoanisole sulfate;/;https://ec.europa.eu/health//sites/health/files/scientific_committees/consumer_safety/opinions/sccs_o_003.pdf  ;the dermal application at the low dose was considered representative of hair dye use conditions. the dermal application at the high dose was designed to favour skin penetration. oral and dermal bioavailability was calculated by comparing blood auc in the toxicokinetic groups and by comparing urine concentrations in the mass balance groups. based on the mass balance studied, oral absorption was 99% in the low dose group and 84% in the high dose group: dermal absorption was 2% or 0.01 mg/cm2 (2.7% when considering the residual amount in the skin) in the low dose – short exposure group and 21% or 0.3 mg/cm2 (22% when considering the residual amount in the skin) in the high dose - 24h exposure group. based on the toxicokinetic study, oral absorption was 97% in the low dose group and 128% in the high dose group: dermal absorption was 2.5% in the low dose – short exposure group and 47% in the high dose - 24h exposure group. tmax were 1 hour after dermal exposure to the low dose and 2 hours after the high dose. terminal half lives ranged from 1.22 hours to 3.9 hours respectively. when absorbed, excretion took mainly place in the urine. in urine, 3 metabolites were identified: 2 mono-acetylated and 1 di-acetylated metabolites of 1,4-diamino-2- methoxymethyl-benzene sulphate. following low dermal exposure, only the di-acetylated metabolite could be detected in the urine. as a minor metabolic pathway, glutathione conjugation occurred resulting in mercapturic acid metabolite. no major qualitative differences in the metabolite profile between the oral and dermal routes were observed.;;;;;;;;;;99.5 ;;gst070-05/24-01, cfq14701 batch 1 (radiolabelled);test substance: 1,4-diamino-2-methoxymethyl-benzene sulphate (wr801337) ;[ring-u-14c]meome ppd sulfate (740 mbq/mmol), 98.5% (hplc) (radiochemical purity);;rat/wistar crl:wi ;;;f;;4 (group 1 to 5) , 6(group 6, 7, 8 and 10) , 7(group 9);;25 mg/kg bw: iv. 25, 100 mg/kg bw: oral. 0.3, 1.25 mg/cm² (25, 120 mg/kg bw): dermal.;5 groups of rats (n=4) were used for the mass balance and 5 groups (n=6) for the toxicokinetic study. rats were exposed to 1,4-diamino-2-methoxymethyl-benzene sulphate by iv at the dose of 25 mg/kg bw, by gavage at the doses of 25 and 100 mg/kg bw and by dermal route at the doses of 25 mg/kg bw in water during 30 minutes and 120 mg/kg bw in DMSO during 24 hours. ;yes;yes, gavage;yes;;;blood: in the toxicokinetic groups, blood was sampled from two rats. in the mass balance groups: total radioactivity in urine, faeces, tissues and organs was determined.;0.25, 0.5, 1, 4, 8, 24 hours post dosing (toxicokinetic groups, blood);0.9% nacl: intravenous groups 1 and 6, milli-q water: oral groups 3, 4 and 7, milli-q and 819051088b: dermal groups 4 and 9, dmso: dermal groups 5 and 10.;the dermal absorption percentages derived from the mass balance group were considered more reliable since the total recovery was within the required criteria of 100 +/- 10%. due to the high oral bioavailability, for the calculation of the mos, the noael does not need to be corrected.;2006;yes;61;adme of 1,4-diamino-2-methoxymethyl-benzene sulfate (wr801337) in the wistar rat. in this adme study, 5 groups of rats (n=4) were used for the mass balance and 5 groups (n=6) for the toxicokinetic study. by dermal route at the doses of 25 mg/kg bw in water during 30 minutes and 120 mg/kg bw in dmso during 24 hours.;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
2-amino-5-ethylphenol HCl ;OECD 417 ;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_085.pdf  ;"plasma level: low dose male, high dose male; low dose female, high dose female; c max (µg/g) : 19.48, 212.8; 8.79 & 7.67, 267.2 & 263.3; t max (h) : 4, 4; 1 & 4, 2 & 4; t 1/2 (h): 9.1, 11.8; 8.9, 9.9; auc (mg*h/L) : 166.1, 4505; 119.3, 6322; c96 (mg/L): 0.02, 1.1716; 0.007, 0.742; at 2 mg/kg/d single dose c max (µg/peq/g): 14.326, repeated dose c max (µg/peq/g): 4.977. plasma concentrations at c max were comparable following the bolus radiolabelled dose on day 14 compared to the single dose in rats. in contrast, the c max level for a single oral dose of triclosan in plasma following repeated daily exposure was decreased in mice, compared to plasma levels following a single dose. it should be noted that tissue distribution data in the murine pk/adme study showed that, at the oral dose of 200 mg/kg body weight/day for 14 days, levels of triclosan in the liver of male mice were approximately 2 times higher than levels in plasma.";;;;;;;;;;;;;;14C-triclosan ;;mouse;;;f & m;;;;2, 200 mg/kg bw/d;single and repeated daily for 14 days ;;yes, diet ;;;;blood and tissue samples;auc were determined following 13 days of triclosan administration in the diet. pharmacokinetics analyses were conducted on blood and tissue samples taken following a dose of 14c-labelled triclosan on day 14 of repeated dosing. at 4 hour;;triclosan is rapidly absorbed as indicated by the time to reach c max. two peaks (2 x t max) in plasma triclosan levels were detected in mice and rats, with peak plasma concentrations occurring after 1 and 4 hours in these 2 species. c max values obtained following 2 versus 200 mg/kg body weight/day did not reflect the 100-fold increase in dose of triclosan. a comparison of the c max data for the low and high doses indicates that the process of absorption may be at least partially saturated at the high dose level and elimination may be enhanced. triclosan appeared to have high systemic exposure following oral administration, based on urinary excretion data (i.e., high levels of radioactivity were excreted in the urine following dosing, indicating good absorption).  in summary, in the 3 rodent studies presented target dose levels of 2 and 200 mg/kg body weight were used in each study, and thus relevant comparisons of exposure between species can be made following single doses of triclosan. the auc data (measured over 96 hours in mice and rats and 168 hours in hamsters) show that the mouse and hamster have much higher levels of exposure (almost 3-fold) compared to the rat. the levels of exposure in the mouse and hamster are shown to be similar. plasma levels at 96 hours were much higher in hamsters than in mice and rats. tissue distribution data in the mouse show that increased levels of triclosan are found in mouse liver compared to plasma. ;;;81;van dijk, animals sacrificed at 96 h. c max =maximal concentrations in blood and tissues, t max =the time required to reach the peak concentration, auc= the plasma area under the concentration-time curve, t1/2= the elimination half-life of the radioactivity, c96=plasma concentration at 96 hr. auc values representative of time of animal sacrifice: 96 h;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;OECD 427;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_085.pdf  ;the auc value calculated for these data was 489000 g*hr/ml. ;;;;;;;;;;;;;;;;mouse;;;;;;;10 mg/kg (22,500, 22,000, and 23,600 ng/mL on days 12, 13, and 14 of dosing);repeated 12 to 14 days ;;yes, diet ;;;;;;;;1997;;92;huntingdon life sciences;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
2-methoxy-methyl-p-phenylenediamine and its sulfate salt ;/;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_123.pdf    ;"plasma concentration(ng/ml) of triclosan at dose (mg/kg/d) : at interim (6months) mean males, sd males; mean females, sd females / at termination (18months) mean males, sd males; mean females, sd females : at 10mg/kg/d : 16800, 4260; 21900, 8220 / 20600, 11100; 21100, 7300. at 30(mg/kg/d): 58900, 15300; 75700, 11500 / 62400, 26100; 98900, 21300. at 100(mg/kg/d): 134600, 25000; 172100, 27200 / 150200, 37400; 169000, 69400. at 200 mg/kg/d : 177600, 49300; 191500, 37700 / 197200, 43100; 236500 ,59900. steady state concentrations: at dose (mg/kg/d) : at interim (ng/ml) in males mean, sd; in females mean,sd / at termination (ng/ml) in males mean, sd; in females mean, sd : at 100(mg/kg/d) : 134600, 25000; 172100, 27200 / 150200, 37400; 169000, 69400 : at 200(mg/kg/d) : 177600, 49300; 191500, 3700 / 197200, 43100; 236500, 59900 : at dose-normalized : 888-1346, --; 958-1721, -- / 986-1502, --; 1183-1972, --.  these data indicate that in chronic dosing studies, plasma levels in mice were slightly higher or comparable to plasma levels in rats (based on dose-normalized data) and much higher than plasma levels in hamsters (greater than 4- to 5-fold). ";;;;;;;;;;;;;;;;mouse;;;f &m;;;;10, 30, 100, 200 mg/kg/d;repeated ;;;;;;;;;;1995;plasma levels in the chronic mouse study were comparable to those in the 14-day study (16800 and 21900 ng/mL in males and females, respectively). ;66;pharmaco lsr. chronic carcinogenicity bioassays;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
2-methoxy-methyl-p-phenylenediamine and its sulfate salt ;/;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_123.pdf    ;"note that the original total values for triclosan (free + conjugates) were in units of ng/mL in blood, not plasma. conversions to values in ng/mL plasma (presented in this table) were based on an average blood volume of 64 mL/kg (range: 58-70 mL/kg) and an average plasma volume of 40 mL/kg (range: 36-45 mL/kg). source for value for rat plasma volume: mcguill and rowan, 1989. average daily dose calculated at approximately 52 weeks (first number) and 104 weeks (second number) for males consuming dietary doses of 300, 1,000, and 3,000 ppm. daily doses (mg/kg/d) were decreased by 15-20% at 104 weeks compared to 52 weeks. plasma concentration (ng/ml) of triclosan in males at dose (mg/kg/d) : at interim (52 weeks) mean, sd; at termination (104 weeks) mean, sd : at 12-9(mg/kg/d) : 21808, 9008; 10576, 3392 : at 40-34(mg/kg/d) : 55024, 12656; 43296, 15760 : at 127-107 (mg/kg/d) : 120368, 44464; 86784, 26416. average daily dose calculated at approximately 52 weeks (first number) and 104 weeks (second number) for females consuming dietary doses of 300, 1000, and 3,000 ppm. daily doses (mg/kg/d) were decreased by 35-40% at 104 weeks compared to 52 weeks. plasma concentration (ng/ml) of triclosan in females at dose (mg/kg/d) : at interim (52 weeks) mean, sd; at termination (104 weeks) mean, sd : at 17-11 (mg/kg/d) : 28160, 12928; 26496, 18032 : at 56-34 (mg/kg/d) : 70624, 22736; 42048, 31888 : at 190-114 (mg/kg/d) : 170656, 32928; 138560, 43648. steady state concentrations at dose (mg/kg/d) in males : at interim (ng/ml) mean, sd/ at termination (ng/ml) mean, sd : at 127-107 (mg/kg/d) : 120368, 44464 / 86784, 26416 : at dose (mg/kg/d) in females: at interim (ng/ml) mean, sd/ at termination (ng/ml) mean, sd : at 190-114 (mg/kg/d) : 170656, 32928 / 138560, 43648; at dose-normalized in males at interim (ng/ml) mean 947 / at termination (ng/ml) 811; at dose-normalized in females at interim (ng/ml) mean 898 / at termination (ng/ml) mean 1216; these data indicate that in chronic dosing studies, plasma levels in mice were slightly higher or comparable to plasma levels in rats (based on dose-normalized data) and much higher than plasma levels in hamsters (greater than 4- to 5-fold).";;;;;;;;;;;;fat 80'023/s;;;;rat;;;f &m;;;;;repeated ;;yes, diet ;;;;;;;;1986;;67;ciba-geigy. chronic carcinogenicity bioassays ;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
2-methoxy-methyl-p-phenylenediamine and its sulfate salt ;OECD 417, OECD 427;https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_123.pdf    ;"plasma level: low dose male, high dose male; c max ( µg/g) : 4.772 & 4.458, 153.4 & 183.3; t max(hr):  1 & 4, 1 & 4; t 1/2 (hr): 12.6, 10; auc (mg*h/L): 63.9, 3237; c96(mg/L): 0.086, 1.25;  at 2mg/kg/d single dose c max (µg/peq/g): 4.772, repeated dose c max (µg/peq/g): 4.491. data from the study in rats that examined auc following both single and repeated doses of triclosan indicate auc levels in plasma did not change after repeated dosing for 14 days.single dose auc (ng*hr /ml) at 2 mg/kg bw/d: 64000, at 200 mg/kg bw/d: 3237000, repeated dose auc (ng*hr/ml) at 2mg/kg bw/d: 77400, at 200mg/kg bw/d: 3581000. additional evidence of a lack of bioaccumulation or bioretention of triclosan is provided by the plasma auc data generated in the definitive rat pk/adme study. in this study, the auc value calculated following an oral dose of 14c-labelled triclosan on day 14 of a repeated triclosan exposure (diet) regimen was comparable to the auc value calculated following a single oral dose. the similarity of the single dose and repeated dose auc values suggests that the amount of triclosan absorbed is equal to that eliminated. together with the similarity in plasma c max values following repeated or single doses, the data show that accumulation of triclosan is unlikely to occur with repeated exposure. ";;;;;;;;;;;;;;;;rat;;;m;;;;2 , 200 mg/kg bw/d;single and repeated daily for 14 days ;;yes, diet ;;;;;at 1-2h;;triclosan is rapidly absorbed as indicated by the time to reach c max. two peaks (2 x t max) in plasma triclosan levels were detected in mice and rats, with peak plasma concentrations occurring after 1 and 4 hours in these 2 species. c max values obtained following 2 versus 200 mg/kg body weight/day did not reflect the 100-fold increase in dose of triclosan. a comparison of the c max data for the low and high doses indicates that the process of absorption may be at least partially saturated at the high dose level and elimination may be enhanced. triclosan appeared to have high systemic exposure following oral administration, based on urinary excretion data (i.e., high levels of radioactivity were excreted in the urine following dosing, indicating good absorption).  in summary, in the 3 rodent studies presented target dose levels of 2 and 200 mg/kg body weight were used in each study, and thus relevant comparisons of exposure between species can be made following single doses of triclosan. the auc data (measured over 96 hours in mice and rats and 168 hours in hamsters) show that the mouse and hamster have much higher levels of exposure (almost 3-fold) compared to the rat. the levels of exposure in the mouse and hamster are shown to be similar. plasma levels at 96 hours were much higher in hamsters than in mice and rats. based on data from the rat pk/adme study, there was no change in auc after 14 days of repeated daily dosing. in summary, both tissue distribution and plasma auc data in hamsters and rats, respectively, provide evidence of a lack of bioaccumulation/bioretention of triclosan. ;1996;;82;van dijk. the study did not investigate the metabolism of triclosananimals sacrificed at 96 h.  c max =maximal concentrations in blood and tissues, t max =the time required to reach the peak concentration, auc= the plasma area under the concentration-time curve, t1/2= the elimination half-life of the radioactivity, c96=plasma concentration at 96 hr. auc values representative of time of animal sacrifice: 96 h;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
triclosan;/;https://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_166.pdf;a direct estimation of absorption was calculated from the comparison of auc values between the oral and i.v. routes of administration in the rat. in this study, it was estimated that an oral dose was 70 to 80% absorbed in rats, based on i.v. and oral auc values calculated from a 5 mg/kg body weight dose ;;;;;;;;;;;;;;;;rat;;;;;;;5 mg/kg bw/d;;yes;yes;;;;;;;"overall, the data from studies in rodents and non-rodents suggest that triclosan is rapidly and highly absorbed from the gastrointestinal tract by all species, with maximum plasma concentrations typically being reached between 4 to 8 hours [van dijk, 1995 (81); lin and smith, 1990 (86); black et al., 1975 (27); siddiqui and buttar, 1979 (87); van dijk, 1994 (80); ciba-geigy, 1976a (88); stierlin, 1972a (89); parkes, 1978b (90)]";1972;;89;stierlin;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
triclosan;/;https://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_166.pdf;;;;;;;;;;;;;;;;;rat;;;;;;;;;;;;;yes;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
triclosan;/;https://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_166.pdf;two peaks in plasma concentration 2 hours (0.278 ppm or 278 ng/mL) and 6 hours (0.264 ppm or 264 ng/mL) ;;;;;;;;;ethanol solution ;;;;;;;rat;;;;;;;;single, 7.5 cm2 of skin ;;;yes;;;;;;;1975;;23;black and howes;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
triclosan;/;https://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_166.pdf;;;;;;;;;;;;;;;;;guinea pig;;;;;;;;;;yes;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
triclosan;/;https://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_166.pdf;"plasma level: low dose male, high dose male; low dose female, high dose female; c max (µg/g) : 7.684, 359.171; 7.357, 384.920; t max (h) : 1, 1; 1, 1; t 1/2 (h): 29.1, 32; 24.5, 27; auc (mg*h/L) : 178, 6010; 79.8, 4298; c96 (mg/L): 0.181, 7.784; 0.071, 4.556; at 2mg/kg/d single dose c max (µg/peq/g): 4.883, repeated dose c max (µg/peq/g): 5.003. plasma concentrations at c max were comparable following the bolus radiolabelled dose on day 14 compared to the single dose in hamsters. tissue distribution data from the hamster study showed persistently higher plasma levels of triclosan compared to levels in liver, kidney, and lung following administration of either the low or high dose of 14c-labelled triclosan (2 or 200 mg/kg body weight/day)liver, kidney, and lung contained the highest levels of triclosan following oral administration, followed by the gastrointestinal tract. levels of triclosan in plasma, liver, kidney, and lung following single versus repeated oral doses of 14c-labelled triclosan are presented. a comparison of levels following single dose versus repeated shows no evidence of accumulation or retention of triclosan in liver, kidney, or lung. taken altogether, the data indicate that triclosan is efficiently eliminated from organs/tissues of the hamster and that there is no accumulation in these tissues after repeated exposure to triclosan. organ or tissue : at 2 mg/kg bw/day in male single dose, in male repeated dose; in female single dose, in females repeated dose /at 200 mg/kg bw/day in male single dose, in male repeated dose; in female single dose, in female repeated dose: plasma : 0.317, 0.209; 0.093, 0.089  / 16.175, 7.898; 7.139, 5.206 ; liver : 0.068, 0.037; 0.017, 0.015 / 3.433, 1.831; 1.361, 1.212; kidney : 0.138, 0.061; 0.019, 0.016/ 3.254, 1.488; 1.249, 0.938; lung : 0.091, 0.062; 0.027, 0.028/ 4.415, 2.204; 1.915, 1.470 (levels in µg of parental equivalents/gram of tissue) ";;;;;;;;;;;;;;;;hamster;;;;;;;2 , 200 mg/kg bw/d;single and repeated ;;yes;;;;;at 1-2h;;triclosan is rapidly absorbed as indicated by the time to reach c max. two peaks (2 x t max) in plasma triclosan levels were detected in mice and rats, with peak plasma concentrations occurring after 1 and 4 hours in these 2 species. c max values obtained following 2 versus 200 mg/kg body weight/day did not reflect the 100-fold increase in dose of triclosan. a comparison of the c max data for the low and high doses indicates that the process of absorption may be at least partially saturated at the high dose level and elimination may be enhanced. triclosan appeared to have high systemic exposure following oral administration, based on urinary excretion data (i.e., high levels of radioactivity were excreted in the urine following dosing, indicating good absorption). in summary, in the 3 rodent studies presented target dose levels of 2 and 200 mg/kg body weight were used in each study, and thus relevant comparisons of exposure between species can be made following single doses of triclosan. the auc data (measured over 96 hours in mice and rats and 168 hours in hamsters) show that the mouse and hamster have much higher levels of exposure (almost 3-fold) compared to the rat. the levels of exposure in the mouse and hamster are shown to be similar. plasma levels at 96 hours were much higher in hamsters than in mice and rats. in summary, both tissue distribution and plasma auc data in hamsters and rats, respectively, provide evidence of a lack of bioaccumulation/bioretention of triclosan. ;1994;;80;van dijk. animals sacrificed at 168 h.  c max =maximal concentrations in blood and tissues, t max =the time required to reach the peak concentration, auc= the plasma area under the concentration-time curve, t1/2= the elimination half-life of the radioactivity, c96=plasma concentration at 96 hr. auc values representative of time of animal sacrifice: 168 h;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
triclosan;/;https://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_166.pdf;"plasma concentration (ng/ml) of triclosan at dose (mg/kg/d) : at interim (52 weeks) in males mean, sd; in females mean, sd / at termination ( 95 weeks for males, 90 weeks for females) in males mean, sd; in females mean, sd: at 12.5 (mg/kg/d) : 1411, 467; 578, 188 / 1322, 232; 655, 148 : at 75 (mg/kg/d) : 5310, 972; 2578, 847 / 8162, 3404; 3683, 664 : at 250(mg/kg/d) : 19390, 3465; 9942, 3055 / 50985, 34197; 43624, 56279. steady state concentrations at 250 (mg/kg/d) in males at interim (ng/ml) mean 19390, sd 3565 / at termination( ng/ml) mean 50985, sd 34197; in females at interim (ng/ml) mean 9942, sd 3055 / at termination (ng/ml) mean 43624, sd 56279; at dose-normalized in males at interim (ng/ml) 78 / at termination 204; in females at interim 40 / at termination 174.  these data indicate that in chronic dosing studies, plasma levels in mice were slightly higher or comparable to plasma levels in rats (based on dose-normalized data) and much higher than plasma levels in hamsters (greater than 4- to 5-fold).";;;;;;;;;;;;fat 80'023/s;;;;hamster;;;;;;;12.5, 75, 250 mg/kg/d;repeated;;yes diet ;;;;;;;;1999;;68;huntingdon life sciences ( chausseaud et al 1994 (ref.93)). chronic carcinogenicity bioassays ;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
triclosan;/;https://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_166.pdf;;;;;;;;;;;;;;;;;rabbit;;;;;;;;;;yes;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
triclosan;/;https://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_166.pdf;in 1 dog study a comparison of urinary and faecal recovery following both oral and i.v. administration suggests an absorption rate of 50% in this species;;;;;;;;;;;;;;;;dog;;;;;;;;;yes;yes;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
triclosan;/;https://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_166.pdf;;;;;;;;;;;;;;;;;dog;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
triclosan;/;https://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_166.pdf;;;;;;;;;;;;;;;;;monkey ;;;;;;;;;;yes;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
triclosan;/;https://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_166.pdf;t max: 12h, c max: 0.5 to 0.7 ppm (500 to 700ng/ml). plasma level ranged from 0.17 to 0.97 ppm (170 to 970 ng/mL). The data from this study showed that plateau levels of triclosan in plasma were reached within 15 days of daily treatment. other pharmacokinetic data (e.g., aucs or t1/2) were not available for triclosan administered via the dermal route.;;;;;;;;0.1;soap containing triclosan (1 mg/ml);;;;;;;monkey/rhesus ;;newborn ;;;;;;single;;;yes;;;;;;"while definitive studies examining tissue distribution over time have not been conducted for dermal application studies, measurements of plasma levels of triclosan in the 90-day study of newborn rhesus monkeys washed with a soap solution containing 0.1% triclosan showed levels of 170 to 970 ng/mL triclosan in plasma. a comparison with c max plasma levels of
500 to 700 ng/mL at the t max of 12 hours after a single application suggests that there is no evidence of bioaccumulation/bioretention of triclosan after repeated dermal exposures. ";1978;;29;parkes;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
triclosan;/;https://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_166.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
triclosan;/;https://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_166.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
triclosan;/;https://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_166.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
triclosan;/;https://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_166.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
triclosan;/;https://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_166.pdf;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;